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Abstract

Second-generation antipsychotics (SGAs), including olanzapine, have been used
widely in the clinic to treat schizophrenia and other psychotic disorders;
however, the metabolic side-effects associated with SGA treatments, including
weight gain, hyperphagia and elevated adiposity, have resulted in reduction of
drug compliance and severe co-morbidities. Both clinical and animal studies
have revealed that olanzapine-induced body weight gain has three typical stages.
Using a female rat model, this study investigated the mechanisms underlying the
alterations in food intake, brown adipose tissue (BAT) thermogenesis and
inflammation responses in these three stages of olanzapine-induced weight gain.
The aim of Chapter 2 was to examine the role of the hypothalamic ghrelin
signalling pathway in olanzapine-induced hyperphagia. Female Sprague-Dawley
rats were orally treated with olanzapine (1mg/kg) or vehicle three times daily by
self-administration of a sweet cookie-dough for 1 week, 2 weeks and 5 weeks,
representing short-, mid- and long-term of olanzapine treatment, respectively.
Olanzapine-induced body weight gain was evidenced throughout the three
treatment cohorts, while elevated daily food intake and circulating ghrelin levels,
as well as most of the hypothalamic ghrelin signalling parameters, including
FOXO1, BSX, pCREB, NPY, AgRP and POMC, were altered towards the
direction in favouring hyperphagia in the short-term treatment cohort only. In
addition, olanzapine-induced weight gain was vanished by restricting food
intake to the level of control, suggesting food intake is the main contributing
factor for body weight gain under short-term olanzapine treatment. Furthermore,
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ICV injection of a ghrelin antagonist (D-Lys-GHRP-6) completely blocked the
effect of olanzapine on elevating food intake and the alterations of the
expressions of downstream hypothalamic ghrelin signalling parameters,
suggesting hypothalamic ghrelin signalling plays a critical role in mediating
hyperphagia under short-term olanzapine treatment.
Following on the effects of olanzapine on body weight gain observed in the mid
to long-term without changes in food intake, Chapter 3 aimed to investigate the
role of BAT thermogenesis and locomotor activity (two important components
of energy expenditure), during the prolonged periods of olanzapine treatments.
The results showed that long-term olanzapine treatment (from day 18 to 34)
induced a significant reduction in BAT temperature, with an acute effect being
observed between 45 and 150 minutes post-treatment in the long-term cohort.
This reduction in BAT temperature in the long-term cohort was associated with
decreased expressions of UCP1 and PGC-1α in BAT. Further, TH mRNA
expressions in hypothalamus and brainstem were both downregulated by
olanzapine treatment in the mid-to long-term, accompanied by a reduction in
percentage brown adipocytes in BAT. These findings suggest that reduced BAT
thermogenesis through downregulation of central sympathetic signals may play
a role in long-term olanzapine-induced weight gain. Finally, locomotor activity
was reduced by olanzapine during the three treatment periods examined,
suggesting a potential role in the entire olanzapine treatment courses.
Emerging evidence from the literature has suggested the association between
obesity, in particular adiposity, and low-grade inflammation in the hypothalamus
and the periphery. Therefore, Chapter 4 investigated the inflammatory effects of
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olanzapine through the three stages of treatment, as well as their relationship
with adiposity and body weight gain. Olanzapine increased average adipocyte
size in visceral WAT, which was highly correlated with elevations of
macrophage infiltration, with the level of macrophage infiltration increased over
time. In addition, olanzapine also lead to elevation of macrophage infiltration in
BAT, but not liver. Furthermore, pro-inflammation cytokines TNFα, IL-1β, and
IL-6 were upregulated by olanzapine in hypothalamus, WAT, BAT, but not liver.
Consistent with the elevation in visceral adiposity (adipose tissue weight),
plasma triglycerides, but not total, HDL, or LDL cholesterol levels, were
elevated by olanzapine throughout the three treatment cohorts. These findings
suggest a close relationship between adiposity and low-grade inflammation
under olanzapine treatment. Moreover, time-related development of low-grade
inflammation along the time courses of olanzapine treatment is also suggested.
In conclusion, this thesis revealed novel mechanisms involving alterations of the
hypothalamic ghrelin signalling affecting food intake, BAT thermogenesis and
locomotor activity, and inflammation responses during the three typical stages of
olanzapine-induced weight gain. In the short-term of olanzapine treatment,
elevated food intake is the main contributor for body weight gain. In this stage,
hypothalamic ghrelin signalling mediates the hyperphagic effect of olanzapine,
which can be blocked by central administration of a ghrelin receptor antagonist.
Reduced locomotor activity and mild elevation of inflammatory responses are
also evidenced at this stage. In the mid-term of olanzapine treatment, the
elevated food intake starts to vanish, while biochemical and morphological
changes in favouring the reduction of BAT thermogenesis begins to be
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evidenced. At this stage, reduced locomotor activity and the enhanced
inflammation responses may be the main contributor to the continued weight
gain. During the long-term of olanzapine treatment, when no elevation of food
intake is evidenced, the reduced BAT thermogenesis, together with the welldeveloped inflammatory responses, may become the main drive for the
maintenance of heavy body weight. Overall, this thesis provides important
guidelines for future research in developing new pharmacological targets with
improved metabolic side-effects.

_____________________________________________________________________________
Qingsheng Zhang

xvii

Acknowledgements
I would like to thank the School of Medicine (as well as the former School of
Health) and the Illawarra Health and Medical Research Institute, University of
Wollongong (UOW) for their support through my PhD studies. I also benefit
from travel grants from the Australian Neuroscience Society and the Faculty of
Science, Medicine and Health, UOW.
To my supervisors Professor Xu-Feng Huang and Associate Professor Chao
Deng, I would like to express my heartfelt thank you for your inspiration,
guidance, encouragements and great supports through the whole periods of my
candidature, especially in those difficult times before my first paper got
published. Your great knowledge and timely guidance since the development of
ideas through to the completion of my papers and thesis was greatly appreciated
and will never be forgotten. I feel fortunate and honoured to have both of you to
be my supervisors.
I would like to thanks my colleagues from the Centre of Translational
Neuroscience, UOW, for your advices, technical supports, and encouragements
for my laboratory experiments and academic writing. In particular, my special
thanks to Ms Hongqin Wang, Ms Jiamei Lian and Ms Meng He, for your great
supports and company through my animal studies and most of my experiments
during my candidature. I also expend my gratitude to Dr Tracey Maddocks for
your advice and help through my animal studies; Dr Teresa du Bois, Mr Martin
Engle, Ms Yizhen Wu, Ms Kelly Liu and Dr Zhixiang Wu for your great advices
for my laboratory experiments; Dr Katrina Weston-Green, Dr Yinghua Yu, Dr
_____________________________________________________________________________
Qingsheng Zhang

xviii

Alex Szabo, Dr Kelly Newell, Dr Elisabeth Frank, Dr Francesca Fernandez and
Ms Natalie Matosin for your advice for my conference presentations and thesis;
Ms Linda Cohen for your professional editing for my published papers.
Finally, I wish to express my love and gratitude to my family. Thanks to my
mum Shaohua, my dad Xibo, my parents-in-law Chuqiao and Xinsong, for
supporting me in these years, especially in those many sleepless nights when
baby-sittings my son. Special thanks to my wife Lili, who has been believing
and supporting me since the first day we met, and sharing a lot of special
moments through the years of my candidature. I thank my son Angus, who has
brought me lots of fun and luck ever since you arrived.

_____________________________________________________________________________
Qingsheng Zhang

xix

CHAPTER ONE

1.1 INTRODUCTION
Schizophrenia is a complex psychotic disorder affecting up to 1.5% of the general
population worldwide (American Psychiatric Association, 2000). Second generation
antipsychotics (SGAs) are the primary treatment for schizophrenia and a number of
other psychotic disorders, due to their claimed better efficacy and reduced
extrapyramidal side-effects (EPS) (Kane et al., 2009; Leucht et al., 2009a; Leucht et al.,
2009b). However, the increased risks of metabolic side-effects, such as weight gain,
elevated adiposity, insulin resistance, and dyslipidaemia, associated with SGA
treatments, have raised increasing concerns from clinicians and researchers (Correll et
al., 2011; Lieberman et al., 2005). In view of the increased risks of co-morbidities
associated with SGA treatments, such as type 2 diabetes, obesity and cardiovascular
disease (Correll et al., 2011; Lieberman et al., 2005), along with the increased metabolic
risks in schizophrenia patients (American Diabetes Association et al., 2004), it is of
high urgency to understand the mechanism of SGA-induced weight gain and other
metabolic side-effects. Although a number of factors have been suggested to contribute
to SGA-induced metabolic side-effects (Deng, 2013; Nasrallah, 2008; Reynolds et al.,
2010; Weston-Green et al., 2013; Zhang et al., 2013), the exact mechanism is still
unclear, possibly due to the fact that these SGAs are working on multiple targets, for
example, food intake, energy expenditure, adiposity, and inflammation, which can
interact with each other. Furthermore, both clinical and animal studies have suggested
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three typical stages in the development of olanzapine-induced weight gain (Huang et al.,
2006a; Pai et al., 2012). Therefore, it is possible that olanzapine is affecting different
systems differently during different stages of treatments and weight gain development.
The present series of PhD studies were designed to elucidate the effects of olanzapine
on these multiple systems, namely food intake, energy expenditure, adiposity and
inflammation, as well as the possible underlining mechanisms, through the three stages
of olanzapine-induced weight gain. A better understanding of these effects and
mechanisms will help the development of a new generation of antipsychotic drugs with
similar or better efficacy yet less metabolic side-effects compared to olanzapine.
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1.2 REVIEW OF THE LITERATURE
[Most of this literature review is based on our published review paper: Zhang et al.
(2013). The role of ghrelin signalling in second-generation antipsychotic-induced
weight gain, Psychoneuroendocrinology, 38(11), 2423-2438. (See Appendix I)]
1.2.1 Schizophrenia
Epidemiological studies suggest that Schizophrenia, with a prevalence rate of up to
1.5% worldwide (American Psychiatric Association, 2000), is associated with a two- to
three-fold increased mortality rate (McGrath et al., 2008). The most common symptoms
of schizophrenia include positive symptoms (including hallucinations, delusions, and
bizarre behaviour), negative symptoms (including social withdrawal, apathy, anhedonia,
poverty of speech, and physical inertia), and cognitive impairments (in areas of
attention, memory and abstract thinking) (Tandon et al., 2009). Although psychosocial
rehabilitation and psychotherapy were also used to treat schizophrenia, the
administration of antipsychotics remains the major resort for schizophrenia treatments
(Tandon et al., 2010). However, the lack of response to antipsychotics in some patients
(Suzuki et al., 2008), along with their various side-effects (Bobes et al., 2003;
Newcomer, 2005; Poyraz et al., 2008), makes the search for a “perfect”
pharmacological treatment for schizophrenia a frustrating task. Therefore, researches on
improving the efficacies and the side-effects of antipsychotic drugs are required.
1.2.2 Antipsychotics: Therapeutics and Side-Effects
Antipsychotics are regarded as the first line of treatment by psychiatrics for
schizophrenia. However, a plethora of EPS, including acute dystonia, akathisia,
parkinsonism, tardive dyskinesia, and tardive dystonia, have been reported to be
_____________________________________________________________________________
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associated with the use of antipsychotics, especially the first-generation antipsychotics
(FGAs) with significant dopamine D2 antagonism (Dayalu et al., 2008).
SGAs, also known as atypical antipsychotics, are of less D2 receptor affinity and higher
affinity to a number of other receptors compared to FGAs, including serotonin 5HT2A,
5HT2C, histamine H1, muscarinic M1 receptors, and α1/α2-adrenergic receptors
(Bymaster et al., 1999; Hewitt et al., 2002; Kapur et al., 2003a; Kroeze et al., 2003).
SGAs have been shown to have greater efficacy as well as less EPS compared to their
first-generation counterparts (Leucht et al., 2009a); hence have been widely used as the
primary treatment option for schizophrenic patients (Kane et al., 2009; Leucht et al.,
2009a; Leucht et al., 2009b).
However, the use of SGAs is associated with significant metabolic side-effects,
including weight gain, diabetes, dyslipidaemia and elevated adiposity (Correll et al.,
2011; Lieberman et al., 2005). These metabolic side-effects have considerably
undermined drug compliance over the long term (Lieberman et al., 2005). Moreover,
obesity and overweight induced by SGA treatments have posed a major risk for a range
of chronic diseases, including type 2 diabetes, hypertension, stroke, cardiovascular
disease, and certain forms of cancer (Flegal et al., 2007; Kaplan et al., 2003; Malnick et
al., 2006), which result in drug withdrawal and symptom relapse.
1.2.3 Time-Related Effects of Olanzapine on Body Weight Gain
Olanzapine is the most widely prescribed antipsychotic in Australia (Mond et al., 2003),
and has significant implications on the treatment of psychiatric illnesses including
schizophrenia. In addition, olanzapine is also regarded as one of the two antipsychotics
associated with the highest risk of inducing weight gain (Nasrallah, 2008). In fact, the
_____________________________________________________________________________
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Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study reported that
approximately one third of schizophrenia patients on olanzapine treatment gained over
7% of body weight over the long term (Lieberman et al., 2005). Despite several studies
have gained some valuable insights (Deng et al., 2007; Han et al., 2008; Huang et al.,
2006a; Huang et al., 2006b; Stefanidis et al., 2009; Weston-Green et al., 2011b),
understanding of the exact mechanisms responsible for this unfavourable side-effect of
antipsychotics is still limited.
Furthermore, clinical and animal studies have both suggested that there are three typical
stages of olanzapine-induced weight gain: the early stage with rapid increase in body
weight accompanied by elevations of food intake; the middle stage with slow body
weight gain and no elevation of food intake; and the final stage with maintenance of the
heavy body weight without food intake elevation (Huang et al., 2006a; Pai et al., 2012)
(Figure 1.1). However, the specific mechanisms underlying the body weight gain sideeffect of olanzapine in each of these stages have not been investigated up to the time of
the present series of studies.

Figure 1.1 Three stages of olanzapine-induced weight gain indicated from both
clinical studies (Left) and animal studies (Right).
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1.2.4 Animal Models for the Three Stages of Olanzapine-Induced Weight Gain
In the search for a suitable rodent animal model for olanzapine-induced weight gain, a
number of issues have been brought into consideration for researchers, including gender
differences, dosage issues and routes of administration.
The difficulty in replicating the human weight gain side-effects in male rodents has
been an apparent issue surrounding the studies of olanzapine-induced weight gain using
animal models (Weston-Green et al., 2010b). Although some studies have showed
successful modelling of olanzapine-induced metabolic dysfunctions in male rats
(Hartfield et al., 2003; Minet-Ringuet et al., 2006a; Shobo et al., 2011; van der Zwaal et
al., 2010), other studies using male rodent models have failed to show a significant
difference (Albaugh et al., 2006; Choi et al., 2007; Minet-Ringuet et al., 2006b; MinetRinguet et al., 2005; Pouzet et al., 2003). In fact, recent reports have suggested that the
fact that female rodents are more sensitive to SGA-induced weight gain is comparable
to that in the clinic (Weston-Green et al., 2010b; Zhang et al., 2013). In the clinic,
female schizophrenia patients are more sensitive to antipsychotic-induced metabolic
side-effects compared to male patients (Bobes et al., 2003; Hakko et al., 2006; Seeman,
2010; Wu et al., 2007). Specifically, females with a psychotic disorder have a 3.6-fold
higher risk of weight gain compared to their male counterparts (Hakko et al., 2006). In
addition, female gender has been considered as a risk factor and predictor for
antipsychotic-induced weight gain in humans (Gebhardt et al., 2009; Smith, 2010).
A wide range of olanzapine dosages have been used in different animal studies, which
may contribute at least partially to the inconsistence in the metabolic side-effect
responses of these animals to the drug. To truly represent the effects of olanzapine on
metabolic dysfunctions in the clinic, it is important to choose a clinically relevant
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olanzapine dosage (i.e. equivalent to the clinically recommended dosage of 520mg/day). Due to the difference in metabolic rates of the drug between human and
rodents, direct translation of the human dosage of olanzapine to the rodent model is
mostly irrelevant (Kapur et al., 2003b). It is widely accepted that a calculation based on
dopamine receptor D2 occupancy and body surface area should be used to convert the
dosage of antipsychotic drugs between species (Kapur et al., 2003b).
A number of different olanzapine administration routes have been used in the literature,
including subcutaneous (Blessing et al., 2006) or intraperitoneal injections (Fell et al.,
2004), oral gavage (Arjona et al., 2004; Coccurello et al., 2006), mini-pumps (Kapur et
al., 2003b; Remington et al., 2011; van der Zwaal et al., 2008) and oral selfadministration (Cope et al., 2009). The injection methods and oral gavage are effective
in investigating the acute in vivo responses, but they may induce potential injury and
extra physical handling and stress to animals, which would affect the results, especially
on hormonal levels and body temperature amongst an array of other parameters
(Balcombe et al., 2004; de Meijer et al., 2010). Continuous administration of the drug
through a mini-pump has the advantage of evenly spreading the olanzapine dosages
throughout the day; however, issues of intolerable acidification of the drug (in order to
achieve the required concentration) (Kapur et al., 2003b) and potential degradation of
olanzapine in the solution overtime (van der Zwaal et al., 2008) have undermined the
application of this method. Finally, oral self-administration of the drug via drinking
water has the problem of maintaining a consistent dosing since olanzapine is not readily
soluble in water (Eli Lilly and Company Material Safety Data Sheet, Zyprexa Tablets,
v1.3, 04/07/2013). Oral self-administration of the drug through a palatable carrier (for
example, peanut butter or cookie dough) is a non-invasive and effective method of
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administration, with reported sensitivity to olanzapine-induced side-effects and superior
response compared to oral gavage or injection methods (Minet-Ringuet et al., 2006b;
Shobo et al., 2011).
The frequency of administration is also a critical issue since it relates to the drug
availability within the animal bodies. In humans, the half-life of olanzapine in the brain
is 75.2 hours (Tauscher, 2002); hence, an administration regime of once per day is
sufficient to maintain the optimal effect of olanzapine. However, the half-life of
olanzapine in the rat brain is only 5.1 hours, although high levels remain through 8
hours after administration (Aravagiri et al., 1999). Therefore, a maximum 8-hourly
administration interval (i.e. an administration regime of at least three times per day)
may be required to minimise the fluctuations in olanzapine levels available in the
animal brains (Kapur et al., 2003b).
In the present PhD project, an established animal model mimicking the effect of
olanzapine-induced body weight gain in humans was used to investigate the effects of
olanzapine (Deng et al., 2007; Han et al., 2008; Huang et al., 2006a; Weston-Green et
al., 2011b). In this female Sprague-Dawley rat model, rats will be treated with
olanzapine three times daily (t.i.d.) at the dosage of 1mg/kg body weight. This dosage
was carefully chosen based on a previous dose-dependent study from our laboratory
(Weston-Green et al., 2011b), and is equivalent to the clinical dosage of approximately
10mg per day for a 60kg person. The administration route for olanzapine is oral selfadministration with the ‘cookie-dough’ method, which has been repeatedly reported as a
non-invasive method mimicking the human self-administration situation (Deng et al.,
2007; Han et al., 2008; Huang et al., 2006a; Weston-Green et al., 2011b). This animal
model has showed the ability to mimic clinical changes of body weight gain and food
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intake induced by olanzapine up to 36 days of treatment (Huang et al., 2006a).
Therefore, this animal model is suitable to investigate the time-related mechanisms of
olanzapine on body weight gain.
1.2.5 Hormonal Effects and Neuronal Control for Energy Homeostasis
1.2.5.1 Hormonal Effects on Energy Homeostasis
Accumulating evidence has revealed that a number of hormones, including ghrelin,
insulin and leptin, amongst others, are related to the regulation of food intake and
energy expenditure, which affect the control of energy homeostasis (Orr et al., 2005;
Schwartz et al., 2005; Wren et al., 2007).
Leptin is an anorexigenic hormone produced by adipocytes in proportion to fat stores.
Leptin exerts its effects on food intake and energy homeostasis through direct
stimulation of the anorexigenic pro-opiomelanocortin (POMC) neurons and direct
inhibition of the orexigenic neuropeptide Y (NPY)/ agouti-related peptide (AgRP)
neurons at the arcuate nucleus of the hypothalamus (Sentissi et al., 2008) (see section
1.2.5.2 for details about these Arc neurons in regulating energy homeostasis). Although
studies on the effect of SGAs on leptin levels appears to be conflicting, a review by Jin
and colleagues reveals that most studies (out of the 30 studies from 1998-2007)
suggested an elevation effect of SGAs on circulating leptin levels, which are positively
correlated with BMI and adiposity (Jin et al., 2008). These studies suggested that the
elevated leptin levels under SGA treatments were likely to be the result, rather than the
cause, of weight gain or adiposity.
Insulin is secreted from the pancreatic β cells during the cephalic and gastric phases of
digestion (Ahrén, 2000), and is responsible for decreasing glucose levels by facilitating
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glucose uptake into glucose-responsive tissues and suppressing glucose production from
the liver (Bouché et al., 2004). There are abundant amount of insulin receptors in the
hypothalamus and brainstem, through which insulin could suppress food intake by
downregulating NPY expression (Plum et al., 2006; Schwartz et al., 1992). In the clinic,
chronic olanzapine treatment leads to elevated insulin levels and insulin resistance
(Oriot et al., 2008; Perez-Iglesias et al., 2008; Sacher et al., 2007; Wu et al., 2008). This
is consistent with animal studies using rats or mice as animal models (Albaugh et al.,
2006; Coccurello et al., 2009). However, in the short-term, olanzapine and clozapine
has been reported to be able to decrease insulin secretion (Chintoh et al., 2008; Chiu et
al., 2006), possibly via blockage of the muscarinic M3 receptor (Johnson et al., 2005;
Weston-Green et al., 2013; Weston-Green et al., 2012).
Ghrelin, produced mainly by the P/D1 cells from the stomach, is a potent hunger
inducing hormone discovered in 1999 (Kojima et al., 1999). The effect of ghrelin on
appetite and weight gain has been evidenced and widely reported (Adachi et al., 2010;
Druce et al., 2005). The secretion of ghrelin by the stomach depends on nutritional
status, with high ghrelin levels preprandially and low levels postprandially. A tri-phasic
effect of SGAs on circulating ghrelin levels has been reported from reviewing 17 human
studies and 7 animal studies (Zhang et al., 2013). Briefly, most of the existing literature
suggests that SGAs, in particular olanzapine and clozapine, increase circulating ghrelin
levels in the acute phase and short-term, while decreased ghrelin levels were evidenced
in the mid-term. However, in the long-term of SGA treatments, ghrelin levels are reincreased. Given the orexigenic nature of ghrelin, the elevation of ghrelin levels under
olanzapine treatments could be a potential cause for its weight gain liability. Therefore,
Chapter 2 of this thesis is focused on investigating this hypothesis.
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1.2.5.2 Neuronal Control for Energy Homeostasis
The hypothalamus has long been recognised as a primary site of central regulation for
energy balance and body weight. Within the hypothalamus, there are a number of key
areas (“nuclei”) which are critical in the regulation of food intake and energy
expenditure. Neurons within the hypothalamic arcuate nucleus (Arc) are regarded as the
“first order” neurons controlling energy balance. These neurons project to “second order”
neurons at other hypothalamic nuclei including the lateral hypothalamus (LH) and its
adjacent perifonical area (PeF), in which the sense of hunger is controlled, while the
ventromedial hypothalamus (VMH) controls postprandial glucose sensing, a component
of meal termination. Besides, the paraventricular nucleus (PVN) was implicated as an
anorexic region, where neurons of thyrotropin-releasing hormone (TRH) and
corticotrophin-releasing hormone (CRH) are located.
The Arc, adjacent to the third ventricle, contains two major populations of “first order”
neurons with opposing effects on energy balance: the NPY/AgRP neurons, expressing
the orexigenic NPY and AgRP, stimulate food intake and reduce energy expenditure;
while on the other hand, the POMC neurons, expressing the anorexigenic peptides
POMC and cocaine- and amphetamine-regulated transcript (CART), inhibit feeding and
promote energy expenditure upon activation. The NPY/AgRP neurons also produce γaminobutyric acid (GABA), which inhibits POMC neurons through synapse on the
GABAA receptors (Cowley et al., 2003). The NPY-Y1 receptor is also responsible for
this inhibition. Besides all these, the hypothalamic Arc has also been identified as the
whole-body energy sensing centre which receives energy homeostatic signals from the
adipocyte-originated molecule leptin and the pancreatic hormone insulin (Morton et al.,
2006; see reviews by Saper et al., 2002; Schwartz, 2006). In brief, both leptin and
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insulin inhibits the NPY/AgRP neurons (Schwartz et al., 1992); leptin also inhibits the
POMC neurons (Cowley et al., 2001; Schwartz et al., 1997), while insulin’s actually
inhibits POMC neurons despite supressing feeding (Hill et al., 2010; Plum et al., 2006).
Both the NPY/AgRP neurons and the POMC neurons project to “second order” neuron
populations in the paraventricular nucleus (PVN) and the lateral/perifonical
hypothalamic area (LHA/PeF), but exerting opposing actions. The NPY/AgRP neurons
produce inhibitory inputs on PVN via the NPY-Y1 receptors and the antagonistic action
of AgRP on the melanocortin-4 receptors (MC4R) (Ollmann et al., 1997), while the
POMC neurons deliver excitatory signals to the PVN through the release of αmelanocyte stimulating hormone (αMSH), a cleavage product of POMC and an
endogenous agonist of MC4R. Anorexigenic hormones thyrotropin-releasing hormone
(TRH) and corticotrophin-releasing hormone (CRH) are produced at PVN. Additionally,
oxytocin is also an important anorexigenic target in the PVN (Atasoy et al., 2012).
Conversely, LHA/PeF neurons are innervated by NPY/AgRP neurons, but inhibited by
POMC neurons. Orexigenic hormone melanin-concentrating hormone (MCH) and
orexin are released by neurons within the LHA/PeF (see review by Valassi et al., 2008).
Atypical antipsychotics, especially olanzapine and clozapine, have a high affinity to the
serotonergic 5HT2A and 5HT2C receptors (Nasrallah, 2008). Serotonin has been shown
to inhibit NPY/AgRP neurons and activate POMC neurons (Coll et al., 2008; Heisler et
al., 2006). Therefore, it seems reasonable for these antipsychotics to act on the
hypothalamic NPY/AgRP neurons and the POMC neurons.
Chronic administration of the clozapine can increase NPY immunoactivity at the Arc in
male Sprague-Dawley rats (Kirk et al., 2006). Similarly, the elevation effect of
risperidone or clozapine on hypothalamic NPY-like immunoactivity (NPY-LI) has also
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been

reported

(Angelucci

et

al.,

2000;

Obuchowicz,

1996).

In

addition,

intracerebroventricular administration of olanzapine has been shown to acutely increase
hypothalamic NPY and AgRP mRNA levels in male Sprague-Dawley rats (Martins et
al., 2010), although no effect had been observed by intraventricular injection in the
same study. Consistently, oral administration of olanzapine

also increased

hypothalamic NPY level in female rats (Weston-Green et al., 2011a), although two
other studies showed no change (Davoodi et al., 2009; Guesdon et al., 2010), possibly
due to different animal model and/or drug dosage used.
With hypothalamic AgRP levels, either an increased (Fernø et al., 2011; Martins et al.,
2010) or no difference (Guesdon et al., 2010) effect has been observed by atypical
antipsychotic treatment so far. Similarly, an effect of either unchanged (Davoodi et al.,
2009) or decreased (Fernø et al., 2011; Weston-Green et al., 2010a) hypothalamic
POMC levels has been reported on atypical antipsychotic administration.
As part of the focus of the present PhD project, ghrelin signalling pathway from
peripheral to central in controlling energy homeostasis has been reviewed (Zhang et al.,
2013). Briefly, ghrelin binds to the ghrelin receptors located at the GI tract and the vagal
afferents, from where the ghrelin signals are transmitted to the DVC of the brainstem.
Alternatively, ghrelin can pass through the blood-brain barrier (BBB) at the DVC and
relay to the hypothalamus, or pass the BBB at the hypothalamus (Banks et al., 2002). At
the Arc of hypothalamus, ghrelin can upregulate NPY and AgRP, and downregulate
POMC expressions, contributing to the orexigenic effect of ghrelin. Activation of the
GHS-R1a receptor at the level of Arc NPY/AgRP cells promotes mitochondria βoxidation, tentatively through the AMPK-carnitine palmitoyltransferase1 (CPT1)uncoupling protein 2 (UCP2) pathways, leading to the upregulation of the
_____________________________________________________________________________
Qingsheng Zhang

13

transcriptional factors FOXO1, BSX and pCREB, and resulting in the increased
expression of the orexigenic neuropeptides NPY and AgRP.
The brainstem, in particular the dorsal vagal complex (DVC), has also been suggested
as another energy homeostasis controlling centre, apart from hypothalamus (Berthoud,
2002). DVC consists of the dorsal motor nucleus (DMN), the nucleus of the solitary
tract (NTS) and the area postrema (AP). DVC controls energy homeostasis through
several levels. First, circulating metabolic hormones (e.g. leptin, insulin and ghrelin)
can pass the BBB through the permeable AP adjacent to the fourth ventricle, signalling
for nutrition status (Wuchert et al., 2009). Second, direct regulation of appetite and food
intake can also be achieved by projections between the hypothalamic Arc, DVC and the
vagus nerve. Third, vagal afferents originated from the gastrointestinal tract synapse at
the NTS of DVC, providing acute information about nutrition status. Finally, NTS
interneurons project to the preganglionic vagal efferent located at the DMN, which then
descend and synapse at the intra-ganglionic neurons at abdominal viscera, regulating
gastrointestinal functions and energy homeostasis (Travagli et al., 2006). However, in
the current PhD project, we will only focus on the hypothalamic control of energy
homeostasis.
1.2.6 Potential Routes of Actions by Olanzapine on Body Weight Gain
Due to the multi-receptor affinity properties of olanzapine (as mentioned in section
1.2.2), a number of mechanisms have been proposed as potential routes of actions by
olanzapine on inducing body weight gain. Most of the previous studies in the literature
have been focusing on the antagonistic effects of olanzapine on specific receptors
located at the hypothalamus, which exert direct effects on energy homeostasis
regulation system by alterations in food intake or energy expenditure. Amongst these
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studies, the antagonistic effects of olanzapine on histaminergic H1 receptor and
serotoninergic 5HT2C receptor have received most attention from researchers (Kirk et
al., 2009). In addition, the role of muscarinic M3 receptor has also been suggested
particularly in the effects on the insulin resistance (Weston-Green et al., 2010a). In fact,
the effects of olanzapine on energy expenditure, which has been implicated by both
clinical and animal studies, may be through this direct action of olanzapine on the
central neuronal control systems of energy homeostasis (see details in section 1.2.7). On
the other hand, the effects of olanzapine on appetite hormones, in particular ghrelin can
also regulate energy homeostasis indirectly through actions of these hormones at the
central neuronal control pathways (see details in section 1.2.6). These different routes of
actions may form potential mechanisms for olanzapine induced body weight gain at
different stages of treatments. Finally, the reciprocal facilitative relations between
obesity and low-grade inflammation have emerged as an important topic in obesity
research, and the effects of antipsychotics on inflammation have been reported (see
details in section 1.2.8). Therefore, a potential role of inflammation on olanzapineinduced weight gain is implicated, given the close relationship between inflammation
and adiposity.
1.2.7 Antipsychotics and Ghrelin Signalling
SGAs produced seemingly controversial effects on circulating ghrelin levels in both
humans and animals. However, a detailed analysis on these studies according to the
length oftreatment reveals a tri-phasic effect of SGAs on ghrelin levels: an initial
upregulatory effect; a downregulatory negative feedback effect in the short- to mid-term;
and a finalincrease effect in the long-term.
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No clinical studies have reported on the acute effect of SGAs on circulating ghrelin
levels, which makes the judgement of the initial effect of SGAs over ghrelin production
difficult. However, one short-term study suggested that eight days of olanzapine
treatment can lead to small but significant increase in pre- and post-prandial total
ghrelin levels (Vidarsdottir et al., 2010), indicating an acute upregulatory effect of
SGAs on ghrelin production. This view is supported by two pharmacological animal
studies which showed that acute olanzapine or clozapine treatments can increase both
pre- and postprandial total ghrelin levels in rodents (van der Zwaal et al., 2012).
Furthermore, our preliminary data also showed that one week of oral olanzapine
treatment can increase plasma total ghrelin levels in rats (Zhang et al.,unpublished data).
Therefore, an initial upregulatory effect of SGAs on circulating ghrelin production is
proposed.
Neuronal control of ghrelin secretion includes vagal (parasympathetic) and sympathetic
pathways. The preprandial elevation and postprandial suppression of circulating ghrelin
levels are both exaggerated by vagalstimulation (Heath et al., 2004). An inhibitory tone
of vagus nerve over ghrelin production has been suggested (Lee et al., 2002; Toshinai et
al., 2001; Weston-Green et al., 2012), which was supported by a truncal vagotomy
study showing that plasma ghrelin was increased by vagotomy in rats (Lee et al., 2002),
and ghrelin secretion is increased during fasting when vagal (parasympathetic) activity
is low. Since olanzapine and clozapine, the two SGAs with highest risk of weight gain,
are both muscarinic M1 and M3 antagonists (Nasrallah, 2008), it is conceivable that the
blockage of vagal (parasympathetic) signalling pathways by these SGAs promote
ghrelin production. However, this view is in contrary to the findings of another
subdiaphragmatic vagotomy study which showed that fasting-induced elevation of
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ghrelin levels was completely prevented by subdiaphragmatic vagotomy, and
significantly reduced by the muscarinic antagonist atropine (Williams et al., 2003). Two
pharmacological studies also suggest that ghrelin secretion is stimulated by
cholinergic/muscarinic agonists, while inhibited by muscarinic antagonists (Broglio et
al., 2004; Hosoda et al., 2008). Further, it is noteworthy that although clozapine is a
muscarinic receptor antagonist, norclozapine (an active metabolite of clozapine) is a
partial agonist of muscarinic receptors (Davies et al., 2005; Li et al., 2005). Therefore,
the individual variations on the clozapine:norclozapine ratio (Couchman et al., 2010)
explain, at least partly, the variations of findings in studies reporting on ghrelin levels
under SGA treatments.
Studies on sympathetic (in particular adrenergic) control of ghrelin production also
provide indirect support for the view that SGAs can upregulate ghrelin production. One
pharmacological study showed that ghrelin secretion in rats was stimulated by an αadrenergic antagonist phentolamine and a β-adrenergic agonist isoproterenol, while
inhibited by an α-adrenergic agonist phenylephrine (Hosoda et al., 2008), suggesting an
inhibitory role of α-adrenergic signalling and a facilitatory role of β-adrenergic
signalling on ghrelin secretion. In addition, ghrelin secretion is stimulated by βadrenergic stimulation in both cultured ghrelinoma cells and fasted mice (Zhao et al.,
2010). Similarly, an earlier study also found that intraperitoneal injections of the
selective α1-adrenergic receptor antagonist prazosin (0.25mg/kg), the α2-adrenergic
receptor antagonist yohimbine (2mg/kg), and the SGA clozapine (10mg/kg)
significantly increased blood active ghrelin levels in male Sprague-Dawley rats
(Murashita et al., 2007b). Since most SGAs are antagonists for α1-/α2-adrenergic
receptors (Nasrallah, 2008), the increase in ghrelin levels under SGA treatments could
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be expected. Taken together, the balance between cholinergic and adrenergic signals
combined with the antagonist and/or partial agonist properties of SGAs on the
corresponding receptors provides a possible explanation for the initial effects of SGAs
on ghrelin production.
After the appearance of the initial upregulatory effect on ghrelin production, during the
short- to mid-term of the SGA treatments, results from clinical studies become more
inconsistent. One study investigated the effect of olanzapine, clozapine, antidepressants
with weight gain, other antipsychotics, and other antidepressants on circulating ghrelin
levels showed that after 8-14 days of treatment, there was no significant difference in
circulating total ghrelin levels amongst treatment groups (Himmerich et al., 2005).
Other short- to mid-term studies suggested that circulating total ghrelin levels are
decreased compared to the baseline or control after 2-6 weeks of SGA treatments
(Komossa et al., 2010; Roerig et al., 2008; Tanaka et al., 2008; Vidarsdottir et al.,
2010). These findings indicate that after the initial upregulatory effect, ironically, SGAs
produced a downregulatory effect on the circulating ghrelin levels during the short- to
mid-term of the treatments in humans, which can cancel out the initial upregulatory
effect or even push the levels further below the baseline. Interestingly, animal studies
also showed a similar trend, with one study showing no difference in active ghrelin
levels (Albaugh et al., 2006) and another study showing decreased total ghrelin levels
(Davey et al., 2012) after 2-3 weeks of olanzapine treatments; although another 2-week
study still shows an upregulatory effect in total ghrelin levels (Weston-Green et al.,
2011b). Together, these data may suggest a secondary downregulatory effect of SGAs
on circulating ghrelin levels, which could be due to the increased body weight and food
intake triggered by the initial SGA treatment. In fact, ghrelin levels are lower in obese
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humans (Tschop et al., 2001), and the SGA-treated patients in the above-mentioned
short- to mid-term clinical studies had significantly increased body weight (Hosojima et
al., 2006; Roerig et al., 2008) or BMI (Komossa et al., 2010), indicating a possible
negative feedback mechanism of reduced ghrelin levels in response to SGA-induced
weight gain.
Clinical studies reporting on ghrelin levels after 8-16 weeks of SGA treatments showed
that neither total (Popovic et al., 2007; Smith et al., 2012; Tanaka et al., 2008) nor
active (Tanaka et al., 2008; Theisen et al., 2005) ghrelin levels during these treatment
periods were significantly different from the baseline or control, indicating a recovery
of ghrelin levels to the baseline after the secondary downregulatory effects of SGAinduced weight gain. These findings are in accordance with an 8-week animal study
which showed that 8 week of olanzapine, haloperidol or vehicle control treatments had
no significant difference in circulating ghrelin levels in mice. Furthermore, the majority
of longer-term studies reporting on ghrelin levels after more than 6 months of SGA
treatments showed an upregulation effect of SGAs on circulating total (Esen-Danaci et
al., 2008; Murashita et al., 2007a; Murashita et al., 2005), active (Murashita et al.,
2007a; Murashita et al., 2005; Palik et al., 2005) or desacyl (Perez-Iglesias et al., 2008)
ghrelin levels, with the exception of two studies (Chen et al., 2011; Kim et al., 2008).
Interestingly, both of these two studies reported on total ghrelin levels only (Chen et al.,
2011; Kim et al., 2008); while the three long-term studies reported on active ghrelin
levels all indicated that SGAs can increase ghrelin levels (Murashita et al., 2007a;
Murashita et al., 2005; Palik et al., 2005). Since acyl ghrelin (n-octanoyl ghrelin) is the
biologically active form of ghrelin which binds to the GHS-R1a receptor to exert its
orexigenic effect (as mentioned earlier in section 2.1), it might be more relevant in the
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context of SGA-induced body weight gain compared to total ghrelin, although SGAs, as
suggested by another study, also increase desacyl (inactive) ghrelin levels in the longterm (Perez-Iglesias et al., 2008). Together, these studies suggested that circulating
ghrelin levels return to the levels of, or even above baseline after long-term SGA
treatments. The exact mechanism for this phenomenon is still unknown, although the reestablishment of a new energy balance after the weight gain induced by SGAs could be
a possible explanation.
In summary, existing clinical and animal studies suggest that SGAs have an initial
upregulatory effect on circulating ghrelin levels during the acute- to short-term
treatment stage. This effect is possibly due to the direct effect of SGAs on ghrelin
production through neuronal regulations over the parasympathetic and sympathetic
pathways. After the initial upregulation, SGA-induced weight gain produced a
downregulatory effect on circulating ghrelin levels during short- to mid-term treatments.
At this stage of treatments, human or animal subjects treated with SGAs have increased
body weight and food intake triggered by the initial SGA treatments, which could
produce a negative feedback control on circulating ghrelin levels, resulting in the
overall seemingly downregulatory effect. Eventually, a new energy balance is reestablished and the negative feedback effects of the increased body weight and food
intake on ghrelin levels are removed, leading to the recovery of circulating ghrelin
levels back to the baseline level or above during the longer term of SGA treatments.
The discrepancies of the results in clinical studies may also be due to differing
medication histories and possible co-treatments within study subjects (in particular
those who had been treated with other antipsychotics), different age range and/or gender
composition, and different ghrelin measurement techniques used in different studies.
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Further, different antipsychotics can have diverse effects on ghrelin secretion. For
example, clozapine tend to have no effect on ghrelin levels in the short-term
(Himmerich et al., 2005; Popovic et al., 2007; Theisen et al., 2005), and risperidone
tend to increase ghrelin levels in the long-term (Esen-Danaci et al., 2008; Murashita et
al., 2005; Palik et al., 2005; Perez-Iglesias et al., 2008). Moreover, differing patient
hormonal states (other than ghrelin) may also affect ghrelin production. For instance,
ghrelin secretion was reduced by insulin (Kamegai et al., 2004; Shrestha et al., 2009),
and increased by cholecystokinin (CCK) (Shrestha et al., 2009) and glucagon (Kamegai
et al., 2004). Finally, differing dietary choices by study subjects could be another
confounding factor for ghrelin production, since a high-carbohydrate diet produced a
more persistent postprandial inhibitory effect on ghrelin secretion than the high-fat diet
(Monteleone et al., 2003; Sánchez et al., 2004), which was presumably due to the
different satiating capacities of these diets.
In the clinic, female has been suggested as a risk factor and predictor for weight gain
associated with SGAs and other antipsychotics (Gebhardt et al., 2009; Smith, 2010). In
fact, the sensitivity of female rodents to the weight gain side-effect of SGAs over males
is comparable to that in the clinic (Weston-Green et al., 2010b). However, only one
human study has reported on gender differences in ghrelin levels under SGA treatments,
but this study showed no gender effect (Himmerich et al., 2005). In contrast, one recent
rodent study reported that plasma ghrelin levels were reduced by olanzapine in females
but not in males (Davey et al., 2012). Further studies are required to compare the gender
differences in the effects of SGAs on ghrelin levels.
In addition to the effects on circulating ghrelin levels, SGAs (in particular olanzapine)
have also been reported to upregulate hypothalamic levels of the GHS-R1a protein and
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mRNA expression (Davey et al., 2012; Zhang et al., 2012). This could be the results of
the initial upregulated ghrelin (especially active ghrelin) levels under SGA treatments.
Growth hormone-releasing hormone (GHRH) and growth hormone secretagogue (GHS)
have been reported to upregulate GHS-R1a mRNA expression in rat pituitaries
(Kineman et al., 1999), and ghrelin has been reported to activate GHS-R1a in the rat
retina (Zaniolo et al., 2011). In addition, ghrelin treatment reversed the down-regulated
GHS-R1a mRNA and protein levels in the rat cerebral cortex on ischemia/reperfusion
injury (Miao et al., 2007), and intravenous injection of ghrelin upregulated GHS-R1a
mRNA at the Arc of the hypothalamus in rats (Nogueiras et al., 2004). Therefore, it is
conceivable that elevated blood ghrelin levels under SGA treatments upregulate
hypothalamic GHS-R1a expression.
As a possible example, it has been recently reported that some of the dopamine D2
receptor is colocalized with the GHS-R1a receptor at the hypothalamus, and
heterodimers of D2 receptor and the GHS-R1a receptor have been found to naturally
exist in cells coexpressing these receptors with functional interactions (Kern et al.,
2012). Since most SGAs are D2 receptor antagonists, it is possible that blocking the D2
receptor by these antipsychotics stimulates the expression of the GHS-R1a receptor by a
compensatory mechanism. In addition, the D2 receptor agonist requires the GHS-R1a
receptor to conduct the anorexic effect (Kern et al., 2012). Conversely, is it conceivable
that SGAs, as D2 antagonists, require the integrity of the GHS-R1a receptor to increase
food intake. In fact, reduced D2 receptor concentration was detected in obese rats as
opposed to lean rats (Fetissov et al., 2002; Palmiter, 2007). Furthermore,
heterodimerization and functional interaction between the GHS-R1a receptor and the 5HT2c receptor has also been identified recently (Schellekens et al., 2013). Since most
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SGAs, in particular those with high weight gain liabilities are 5-HT2C antagonists; it is
possible that these SGAs may regulate ghrelin signalling via antagonising the 5-HT2c
receptors, or vice versa. Finally, the heterodimers between the GHS-R1a receptor and
the melanocortin-3 receptor (MC3R) (Rediger et al., 2011), and between the GHS-R1a
receptor and the dopamine D1 receptor (Jiang et al., 2006) have been reported.
Based on existing data, it is conceivable that SGAs upregulate ghrelin production
through a complex regulation system involving the balance between sympathetic and
parasympathetic nervous systems. The elevated ghrelin signals are conducted to the
hypothalamus, the energy homeostasis regulation centre, through neuronal afferent
pathways, or to a lesser extent, through direct actions at the Arc or DVC by passing
through the BBB. The GHS-R1a receptor expression at the hypothalamus is also
upregulated under SGA treatments (Davey et al., 2012; Zhang et al., 2012), possibly
through the elevated circulating ghrelin levels. The elevated ghrelin signals integrated
at the hypothalamus upregulate the Arc orexigenic neuropeptides AgRP and NPY,
possibly through the activation of the transcription factors BSX, FOXO1 and pCREB.
Innervated NPY/AgRP neurons at the Arc can thus inhibit the nearby POMC neurons,
further enhancing the hyperphagic signals of ghrelin, leading to body weight gain.
1.2.8 Antipsychotics and Energy Expenditure
Energy expenditure, representing half of the energy balance equation, has also been
suggested to play an important role in SGA-induced weight gain, apart from the effects
of food intake (Arjona et al., 2004; Stefanidis et al., 2009; van der Zwaal et al., 2012).
Both clinical and animal studies reveal that there are three stages of SGA-induced
weight gain: the initial stage with rapid increase of bodyweight accompanied with
elevated food intake, the middle stage with slow body weight gain and no elevation of
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food intake, and the late stage with maintenance of the heavy body weight without
elevated food intake (Huang et al., 2006a; Pai et al., 2012). Therefore, it is possible that
energy expenditure is contributing, at least partly, to the heavy weight maintainence at
the late stage of SGA-induced weight gain.
Clinical studies showed that SGAs had either a reduction (Procyshyn et al., 2004;
Sharpe et al., 2009; Virkkunen et al., 2002) or nil (Gothelf et al., 2002; Graham et al.,
2005; Roerig et al., 2005) effect on resting energy expenditure (REE). These
inconsistance may due to the heterogenious nature of the human subjects, the different
dosages of SGAs prescribed, and previous medical history of the subjects. Results from
animal studies, as expected, were

more consistent, with most studies showing an

reduction effects of SGAs on one or more of the energy expenditure components: either
a reduction of locomotor activity or gross motor activity (as an indicator or reduced
physical activity) (Arjona et al., 2004; Evers et al., 2010; Karl et al., 2006; Kumar et al.,
2003; Mann, 2009; Stefanidis et al., 2009; van der Zwaal et al., 2010), a reduction of
resting energy expenditure (Coccurello et al., 2009), or a reduction of BAT temperature
or core body temperature as an indicator of reduced thermogenesis) (Blessing et al.,
2003; Evers et al., 2010; Stefanidis et al., 2009). Furthermore, metabolically active
brown adipose tissue (BAT) has been identified in adult humans (Nedergaard et al.,
2007; 2010), with its functional thermogenic protein, uncoupling protein1 (UCP1)
found in humans (Cinti, 2006), suggesting that the involvement of BAT thermogenesis
in SGA-induced weight gain observed in rodents may have clinical relevance in humans.
Therefore, it is intriguing to investigate the time-dependent effects of olanzapine on
energy expenditure, in particular BAT thermogenesis and locomotor activity, with was
the focus of Chapter 3 of this PhD project.
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1.2.9 Antipsychotics and Inflammation
Accumulating evidence has suggested that obesity and type 2 diabetes are associated
with the development of low-grade inflammatory responses (Ouchi et al., 2011). In fact,
adipose tissue is able to produce inflammatory cytokines such as TNFα, interlukins (IL;
including IL1, IL6, IL8 and IL10), complement cascade factors (plasminogen activator
inhibitor-1

(PAL-1),

fibrinogen,

angiopoitein-related

proteins,

metallothionein,

complement factor 3) and chemoattractant cytokines (monocyte chemitactic protein-1
(MCP-1) and macrophage inflammatory protein-1α) (Gerhardt et al., 2001).
Furthermore, it has been reported that macrophage infiltration in WAT increases in
proportion to BMI and adipocyte hypertrophy (Cancello et al., 2005; Curat et al., 2004;
Weisberg et al., 2003). In particular, cafeteria diet induced obesity and metabolic
syndrome have been reported to be associated with liver and adipose tissue
inflammation and macrophage infiltration (Sampey et al., 2011). In addition,
hypothalamic inflammation has also been suggested to contribute to the pathogenesis of
obesity in response to high fat feeding (Kleinridders et al., 2009).
However, the effects of olanzapine on central or peripheral inflammation have received
little attention. One earlier animal study reported that female rats received olanzapine
treatment (2mg/kg) had elevated plasma levels of IL-8 and IL-1β, while both male and
female rats received olanzapine treatment demonstrated increased adiposity and
macrophage infiltration into adipose tissue (Davey et al., 2012). A clinical study
reported that 14 days of olanzapine treatment (5-10 mg/d) led to increased serum levels
of TNFα and PAI-1 compared to control in healthy male volunteers (Fountaine et al.,
2010). Therefore, Chapter 4 of this PhD project will be investigating the effect of
olanzapine on macrophage infiltration and the mRNA expressions of inflamatory
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cytokines such as TNFα, IL1β and IL6 in adipose tissues, liver and the hypothalamus,
as well as their relationships with body weight gain and adiposity.
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1.3 AIMS
1.3.1 General Aim
To examine the time-related effects of olanzapine, a second-generation antipsychotic
drug with high metabolic side-effect liabilities, on hypothalamic ghrelin signalling
pathways to enhance food intake, brown adipose tissue thermogenesis and locomotor
activity to reduce energy expenditure, and inflammatory signalling markers, in order to
elucidate the molecular mechanisms of olanzapine-induced weight gain.
1.3.2 Specific Aims
The specific aims of this research were to:
1. Evaluate the time-related role of hypothalamic ghrelin signalling pathway in
olanzapine-induced hyperphagia and weight gain in an established female rat model;
2. Examine the time-related effects of olanzapine on brown adipose tissue
thermogenesis and locomotor activity during the prolonged time courses of
treatment in an established female rat model;
3. Investigate the time-related effects of olanzapine on the mRNA expressions of
proinflammation markers TNFα, IL-1β and IL6 at hypothalamus, brown adipose
tissue, visceral white adipose tissue and liver, during the three courses of treatment
in an established female rat model.
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1.3.3 Hypotheses
1. Olanzapine will increase circulating ghrelin levels and the hypothalamic parameters
at the ghrelin signaling pathway in a time-dependent manner, which will contribute to
the elevated food intake and body weight gain. In addition, the effect of olanzapine on
food intake will be blocked by central injection of a ghrelin receptor (GHSR1a)
antagonist (D-Lys3-GHRP-6);
3. Olanzapine will reduce brown adipose tissue thermogenesis and locomotor activity in
a time-dependent manner, with higher magnitude of reduction in the longer term of
treatment;
4. Olanzapine will trigger macrophage infiltration at adipose tissues and elevation of
mRNA expressions of inflammation markers TNFα, IL-1β and IL6 at hypothalamus,
brown adipose tissue, visceral white adipose tissue and liver at different stages of
treatments.
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1.3.4 Significance
SGAs, including olanzapine, are effective and widely prescribed treatments for
schizophrenia and other mental disorders in the clinic. However, the metabolic sideeffects of these antipsychotic drugs, including weight gain, have led to severe
comorbidities including cardiovascular disease and stroke. In addition, these metabolic
side-effects have also led to reduced drug compliance in some patients. These factors,
along with the higher incidence of obesity and type 2 diabetes in schizophrenia patients
as compared to the general population, have urged the understanding of the mechanisms
behind these metabolic side-effects triggered by SGA treatments, and hence the
development of new treatment regimens for schizophrenia patients. Although studies in
the past decade have provided some insights into several hypotheses for SGA-induced
weight gain, the exact mechanism remains unclear, and the current literature suggests
that multiple pathways affecting different aspects of energy homeostasis, including
hyperphagia, reduced energy expenditure, adiposity and inflammation, may coexist to
facilitate this metabolic disorder under SGA treatments.
Since SGA-induced obesity has three typical stages, the mechanisms for these stages
may be different. Exploring the time-related effects of olanzapine, a SGA with high
weight gain liabilities, on hypothalamic ghrelin signalling pathways relating to food
intake, brown adipose tissue thermogenesis and locomotor activity related to energy
expenditure, and the peripheral and central inflammatory responses, will help
elucidating the mechanisms of olanzapine-induced weight gain from several interrelated
angles. Results from the present study may provide guidelines for future clinical trials
targeting one or some of these aspects related to olanzapine-induced weight gain, and
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ultimately improve the treatments and quality of life for schizophrenia patients in
different stages of treatments.
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1.4 GENERAL METHODS
1.4.1 Ethics Statement
This study was approved by the Animal Ethics Committee, University of Wollongong
(Application Approval #: AE10/18 and AE11/18), and complied with the ‘Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes’ (Australian
Government National Health and Medical Research Council, 2004), which is in
accordance with the International Guiding Principles for Biomedical Research
Involving Animals. All efforts have been made to minimise animal stress and prevent
suffering.
1.4.2 Animals, Diet and Drug Treatments
Female Sprague-Dawley rats (Animal Resource Centre, Perth, WA, Australia), initially
weighting 201-225g, were individually housed at 22⁰C, 12-h light-dark cycle (lights on
at 07:00h). All animals had ad libitum access to water and a standard laboratory chow
diet (3.9 kcal/g; 10% fat, 74% carbohydrate and 16% protein). After one week of
acclimatization (except for the ‘Time-dependent experiment’, which is detailed in
1.4.3), animals were trained to self-administer the placebo sweet cookie-dough to ensure
the timely delivery of drugs or vehicle in the experimental days (except for the ICV
injection experiment, where no microchip was injected and in which case animals were
trained for cookie-dough self-administration after one week of acclimatization).
A cookie-dough (3.5kcal/g; 62% carbohydrate, 22% protein, 6% fibre, 10% vitamins
and minerals) method was employed as previously reported (Deng et al., 2012; WestonGreen et al., 2011b). The cookie-dough method is a non-invasive and effective way of
olanzapine administration method, with reported sensitivity to olanzapine-induced side_____________________________________________________________________________
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effects and superior response compared to oral gavage or injection methods (MinetRinguet et al., 2006b; Shobo et al., 2011). Briefly, a mixture of cornstarch (30.9%),
sucrose (30.9%), gelatine (6.3%), casein (15.5%), fibre (6.4%), minerals (8.4%) and
vitamins (1.6%) was produced. Three times per day, a small cookie-dough
(approximately 0.3g) mixed with either olanzapine (1 mg/kg body weight) (Eli Lilly,
Indianapolis, IN, USA) or placebo were served to the corresponding animals. The
cookie dough contains negligible amount of calorie as compared to the daily food intake
for these rats (accounting for approximately 3-4% of total daily calorie intake). Animals
were observed during the administration period to ensure complete consumption of the
pellets. The dosage of olanzapine (1 mg/kg body weight, three times per day) were
based on our prior studies (Deng et al., 2012; Weston-Green et al., 2011b), which were
clinical relevant calculated based on D2 receptor occupancy (Kapur et al., 2003b). Rats
were closely housed in a room occupied by only female rats, which ensures that the
ovarian cycles of all female rats are synchronized (Lian, 2013).
1.4.3 Experimental Design
To examine the time-related effects of olanzapine on food intake (Chapter 2), energy
expenditure (Chapter 3), as well as inflammation (Chapter 4), a time-dependent study
(Animal Study 1; see Section 1.4.3.1) was performed. Data collected from this animal
study will be used in part of Chapter 2, Chapter 3 and Chapter 4.
In addition, in order to determine the main contributor (food intake or energy
expenditure) for the rapid weight gain at the short-term of olanzapine treatment, a pairfeeding study was conducted (Animal Study 2; see Section 1.4.3.2), and data from
which will be used in Chapter 2 only. Finally, to determine the causal role of central
ghrelin signalling in olanzapine-induced increase of food intake in the short-term, an
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ICV injection study (Animal Study 3; see Section 1.4.3.3) was performed to serve data
for part of Chapter 2 only.
1.4.3.1 Time-Dependent Study (Animal Study 1)
Rats were randomised into either olanzapine (O) or control (C) treatment groups, with
three treatment duration cohorts: short-term (8 days), mid-term (16 days) and long-term
(36 days) (6 groups; n=12/group). Food intake and body weight were measured every
second day. After one week of acclimatization, a Bio-Thermo microchip “LifeChip”
(Destron Fearing, South St. Paul, MN, USA) was inserted into the interscapular brown
adipose tissue (Figure 1.2) with independent packaged disposable sterilized needles.
The positions of the microchips were visually confirmed post-euthanasia. After one
week of recovery, animals were trained to self-administer the placebo sweet cookiedough to ensure the timely delivery of drugs or vehicle in the experimental days.

Figure 1.2 Example of the temperature detection microchip being placed right into
the IBAT. (This was double-checked for each rat after euthanasia.)
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The time frames chosen in the current study were based on evidence observed from both
clinical and animal studies, which suggested that along the time course of olanzapineinduced weight gain, there are three typical stages: the initial stage with rapid increase
of body weight accompanied with elevated food intake, the middle stage with slow
body weight gain and no elevation of food intake, and the late stage with maintenance
of the heavy body weight without elevated food intake (Deng, 2013; Huang et al.,
2006a; Pai et al., 2012).
1.4.3.2 Short-Term Pair-Feeding Study (Animal Study 2)
Rats were randomised into 2 groups: pair-fed olanzapine (PO) and pair-fed control (PC)
(n=12/group). Rats then received 8 days of treatments similar to the short-term cohort in
Animal Study 1, except that the lab-chow provided was not ad libitum, but with
restricted food intake for both control and olanzapine groups to 80% of the control
group’s food intake based on the measurements at the previous time point. Body weight
were measured every second day.
1.4.3.3 ICV Injection Study (Animal Study 3)
After acclimatization, a 24-guage cannula was surgically implanted under anaesthesia
into the lateral ventricle of each rat (1.0mm posterior to the bregma, 1.5mm lateral to
the midline, and 3.5mm below the top of skull) (Paxions et al., 2007). All rats were
allowed to recover for one week with close monitoring of post-surgery symptoms. Rats
were orally administered with either olanzapine (1mg/kg BW) or control cookie-dough
TID for four consecutive days. On the fifth day, 30 minutes before oral cookie dough
administration, rats were injected with 5µL of saline, low dose (3nmol) GHS-R1a
blockade (D-Lys3-GHRP-6; Tocris Bioscience, Ellisville, USA), high dose (30nmol)
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GHS-R1a blockade, or high dose GHS-R1a blockade followed by rat ghrelin (200 pmol;
Tocris Bioscience, Ellisville, USA), via the cannula during 15.00-16.30h (during the
light phase when the normal oral drug administration was delivered). The ICV injection
dosages were chosen based on previous studies (Asakawa et al., 2003; Kola et al., 2005;
Nakazato et al., 2001; Shintani et al., 2001). Foods were removed from the cages before
the injection and reintroduced after cookie-dough administration. Food intake was
measured 1h, 2h, 4h, 18h and 24h post injection. After four days of washout, rats were
reintroduced to the original oral treatment regime of olanzapine or control for another
four days. On the fifth day, rats were injected with the same drugs as in the first ICV
injection, and euthanized 1.5h post-injection.
1.4.4 Euthanasia and Tissue Collection
Two hours after the last treatment in Animal Studies 1 and 2, and 1.5 hours after the last
injection in Animal Study 3 (between 12:00h and 14:00h), rats were euthanized by fast
CO2 infusion (Deng et al., 2012; Han et al., 2008; Weston-Green et al., 2011b).
Blood samples were collected into EDTA tubes from the left ventricle of the heart;
plasma was separated and stored at -80oC. For ghrelin measurement, blood was treated
with 0.8mM Pefabloc SC (Sigma-Aldrich) and acidified with HCl to a final
concentration of 0.05N.
In Animal Studies 1 and 2, brains were dissected on an ice plate immediately after
euthanasia, snap-frozen in liquid nitrogen and stored in -80oC. In Animal Study 3,
whole brains were snap-frozen, cut at 500 µm sections ranging from Bregma -2.16 mm
to -3.66 mm based on a standard rat brain atlas (Paxions et al., 2007), using a cryostat
(Leica CM 1950; Leica Microsystems, Wetzlar, Germany) with the temperature set at _____________________________________________________________________________
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18°C. The Arc was dissected using a Stoelting Brain Punch (#57401, Wood Dale,
Stoelting Co, USA) in an overlapping pattern over the 3rd ventricle. The punched tissue
principally contained arcuate nucleus, but we cannot rule out the inclusion of adjacent
brain areas, so the punched tissue was named as the mediobasal hypothalamus (MBH).
In Animal Study 1, White adipose tissue (inguinal, mesenteric, peri-renal and periovary) and brown adipose tissue (inter-scapular) were dissected and individually
weighed. Liver, IBAT and periovary WAT (as a representative for visceral WAT) were
dissected and cut into two halves: one half was snap-frozen and stored in -80oC, and the
other half was fixed overnight by immersion at 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). The fixed samples were then dehydrated, cleared, and
embedded in paraffin.
1.4.5 Brown Adipose Tissue Temperature Measurements
In Animal Study 1, the instant BAT temperature data was detected by the microchip (an
example picture is shown in Figure 1.2) and received by a remote pocket reader “Pocket
Reader EX” (Digital Angel Corp., South St. Paul, MN, USA). BAT temperature
measurements were conducted 2 hours and 6 hours after the 7am and 11pm drug
treatments every second day. To determine whether there is a circadian effect over the
effect of olanzapine on BAT temperature, BAT temperature up to 3 hours immediately
post treatment was measured after 7am (light phase) and 11pm (dark phase) (Figure
1.3), two days before euthanasia.
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Figure 1.3 Time of drug administration and BAT temperature measurements
during the day.

1.4.6 Open Field Tests
In Animal Study 1, to determine the effect of olanzapine on locomotor activity during
the three different treatment courses, open field tests were performed three days before
euthanization for each cohort (Day 5, Day 13 and Day 31 for the short-, mid- and longterm cohorts, respectively). The open field test protocol was described previously (Deng
et al., 2012; Weston-Green et al., 2011b). Briefly, each rat was placed in the centre of a
black rectangular arena (60x60cm2, 40cm high) with an average light exposure of 25
lux. The behaviour of the rats was recorded by a video camera from the top for 30
minutes. Locomotor activity was analysed using EthoVision Color-Pro software
(Noldus Information Technology, Wageningen, The Netherlands). Total distance moved
(cm) and average velocity (cm/s) were measured.
1.4.7 Western Blotting
The hypothalamus (for Animal Studies 1 and 2), MBH (for Animal Study 3) and BAT
(for Animal Studies 1 only) were homogenised in 10vol (v/w) homogenising buffer
(containing NP40, Protease Inhibitor Cocktail, 1mM PMSF and 0.5mM βglycerophosphate). Total protein concentrations were determined by DC-Assay (Bio_____________________________________________________________________________
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Rad, Hercules, USA), detected by SpectraMax Plus384 absorbance microplate reader
(Molecular Devices, USA). Samples were heat-treated in Laemmli buffer at 95oC,
loaded to 8% SDS-PAGE gels for fractionation, and then transferred onto ImmunBlotTM PVDF membranes (Bio-Rad, Hercules, CA, USA). The block consists of 5%
BSA in TBST.
The membranes were then incubated with POMC, GHS-R1a, pCREB(Santa Cruz
Biotechnologies; dilution factor 1:200), FOXO1 (Cell Signalling Technology; dilution
factor 1:1000), UCP1 or peroxisome proliferator-activated receptor gamma coactivator1α (PGC-1α) (Santa Cruz Biotechnologies; dilution factor 1:500) antibody in TBST
containing 1% BSA overnight at 4oC. Secondary antibodies were anti-rabbit (for
POMC, FOXO1, pCREB and PGC-1α) or anti-goat (for GHS-R1a and UCP1) IgG
conjugated with horseradish peroxidase (Santa Cruz Biotechnologies, USA; dilution
factor 1:3000 for PGC-1α and UCP1, and 1:5000 for the rest). For visualization, ECL
detection reagents were used and films were exposed on the AGFA CP1000 Tabletop
Processor (COD Medical, USA). Films were then analysed using the Quantity One
software, connected to GS-690 Imaging Densitometer (Bio-Rad, Hercules, USA).
1.4.8 Quantitative Real-Time PCR (qRT-PCR)
For Chapter 2 and Chapter 3, TaqMan qRT-PCR technique was used. Total RNA was
extracted from the hypothalamus (in Animal Studies 1 and 2, or MBH in Animal Study
3) and brainstem (for Animal Study 1 only) with PureLink RNA extraction kit (Life
Technologies, NSW, Australia) according to the manufacturer’s protocol. First-strand
cDNA was synthesized with VILO cDNA synthesis kit (Life Technologies, NSW,
Australia) with 20µL reaction volume. qRT-PCR was carried out in triplicates using
TaqMan Gene Expression Assays (Life Technologies, NSW, Australia) on
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LightCycler480+ (Roche, Penzberg, Germany). The results were normalized to β-actin
(cat. no. 4252640E; Life Technologies, NSW, Australia), and were expressed as folds
different from control. The assay identifications of the target genes were: Npy
(Rn01410145_m1),

Pomc

(Rn00595020_m1),

Agrp

(Rn01431703_g1),

Ghsr

(Rn00821417_m1), Foxo1 (Rn01494868_m1), Bsx (Rn04244809_m1), and tyrosine
hydroxylase (TH) (Rn00562500_m1) (Life Technologies, NSW, Australia).
For Chapter 4, CyberGreen qRT-PCT technique was used. The qRT-PCR protocol was
adopted from a previous report from our group (Yu et al., 2013). Briefly, total RNA
from hypothalamus, BAT, WAT and liver was extracted using the Aurum total RNA
mini kit (Bio-Rad Laboratories, Hercules, CA) and reverse-transcribed with the highcapacity cDNA reverse transcription kit (AB Applied Biosystems, California, USA).
qRT-PCR was performed for TNFα, IL-1β and IL-6 in a 20 μl final reaction volume
using SYBR green I master in a Lightcycler 480 (F. Hoffmann-La Roche Ltd,
Switzerland). Amplification was carried out with 45 cycles of 95°C for 10 seconds,
60°C for 30 seconds and 72°C for 30 seconds. The results were normalized to GAPDH,
which served as the internal control. Experiments were performed in triplicates.
The choice of different qRT-PCR techniques was based on the limited availability of the
homogenised brain tissue, as well as the availability of qRT-PCR assays.
1.4.9 Enzyme Immunoassay (EIA)
Hypothalamic NPY levels were determined by the NPY EIA kit (Phoenix
Pharmaceuticals, CA, USA) using the hypothalamic homogenates collected for
Western-blot in Animal Study 1. Plasma ghrelin levels were detected by the ghrelin
(total) EIA kit (Phoenix Pharmaceuticals, CA, USA).
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1.4.10 Histology
To access the morphology of the adipocytes, the paraffin-embedded IBAT tissue was
section-sliced (4μm/section) and treated with hematoxylin and eosin-staining
immediately after mounting (n=6/group). Ten areas per section (per rat) containing
mixed brown and white adipocytes were randomly captured with a Syntec STK1160
CCD camera (Syntec Semiconductor Co. Ltd., Taipei, Taiwan) at 10x objective. The
percentage area of the multilocular brown adipocytes over the total area was measured
by the software ImageJ 1.44p (Wayne Rasband, National Institutes of Health, USA).
1.4.11 Immunohistochemistry (IHC)
The paraffin-embedded tissues (in particular, liver, BAT and WAT; n=6/group) were
section-sliced (4μm/section) at 40 μm intervals, mounted towards charged glass slides,
deparaffinized in xylene, stained for F4/80 as described by Weisberg et al. (2014), and
counter-stained briefly in hematoxylin. Ten fields per section (per rat) from each of the
target tissues were randomly captured with a Syntec STK1160 CCD camera (Syntec
Semiconductor Co. Ltd., Taipei, Taiwan) at 10x objective as described in Zhang et al.
(2014). The total number of nuclei and the number of nuclei of F4/80-positive cells
were counted for each field by the software ImageJ 1.44p (Wayne Rasband, National
Institutes of Health, USA). The percentage of F4/80-positive cells for each sample was
calculated as the total number of F4/80-positive nuclei over the total number of nuclei
in the 10 randomly selected fields. For WAT, average adipocyte cross-sectional area
was also analysed using the ImageJ 1.44p software.
1.4.12 Statistical Analysis
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The statistical software, SPSS (version 15, SPSS, Chicago, IL, USA) was used to
perform all analysis. Independent sample t-tests were used on daily food intake,
cumulative weight gain, circulating ghrelin and hypothalamic GHS-R1a, NPY, AgRP,
POMC, BSX, FOXO1 and pCREB levels, and BAT UCP1 and PGC-1α expressions,
BAT TH mRNA expressions, and percentage of the multilocular brown adipocyte area
at IBAT. One-way ANOVAs were used to compare the hourly food intakes, circulating
ghrelin levels, and levels of GHS-R1a, NPY, AgRP, POMC, BSX, FOXO1 and pCREB
at the MBH, while repeated-measures ANOVA were used to access comparative
differences in BAT temperature. Two-way ANOVA was used to determine the
olanzapine and time effect for tissue weight and body weight gain data, TNFα, IL-1β
and IL-6 mRNA expressions, percentage of F4/80-positive cells, average adipocyte size,
and plasma lipid profile data. Post-hoc Tukey-HSD test was used for multiple
comparisons. Levene’s tests of equality of error variances were performed to check for
heteroscedasticity. Correlations were identified by Pearson’s correlation. Data were
expressed as mean ± SEM, and P < 0.05 was considered statistically significant.
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1.5 OVERVIEW OF THESIS
SGAs, in particular olanzapine, are commonly used in the clinic to treat schizophrenia
and other psychotic disorders. The metabolic side-effects, including body weight gain,
induced by SGA treatments have attracted great attention from clinicians and
researchers due to the resulted comorbidities and drug incompliance. However, the
mechanism of olanzapine-induced weight gain is still unclear. Previous evidence from
both human studies and animal studies suggest that there are three typical stages of
olanzapine-induced weight gain, with differential changes in food intake and body
weight gain at each stage. Central ghrelin signalling through the hypothalamus has been
suggested to affect food intake and energy homeostasis, which may contribute to the
rapid weight gain at the early stages of olanzapine-induced weight gain. Reduced
energy expenditure, in particular thermogenesis from the brown adipose tissue and
physical activity, has also been suggested as a contributor to olanzapine-induced weight
gain especially at the late stages. Last but not least, low-grade central and peripheral
inflammation is closely related to weight gain and adiposity, which may also play a role
in olanzapine-induced weight gain. However, studies on the time-related effects of
olanzapine on each of these systems affecting body weight gain are limited or lacking.
Therefore, elucidating the effects of olanzapine on each of these systems as well as their
roles in each stage of olanzapine-induced weight gain is required to provide guidelines
of prescription and further research to improve the treatment for schizophrenia at each
stage of treatments.
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1.5.1 Hypothalamic Ghrelin Signalling Mediates Olanzapine-Induced Hyperphagia and
Weight Gain in Female Rats
Excessive weight gain is a major metabolic side-effect of SGAs in the treatment of
schizophrenia. Ghrelin is an orexigenic hormone secreted mainly from the stomach,
which can induce weight gain and hyperphagia through regulating neuropeptides at the
hypothalamus. Accumulating evidence implicates a relationship between ghrelin
signalling and SGA-induced hyperphagia and weight gain. We report that olanzapine
potently and time-dependently upregulate ghrelin and ghrelin signalling, leading to
hyperphagia and weight gain in female Sprague-Dawley rats, an action reversed by
intracerebroventricular injection of a GHS-R1a antagonist. These findings indicate a
crucial role of ghrelin signalling in hyperphagia induced by olanzapine, supporting the
notion that GHS-R1a antagonist may be useful for pharmacological treatment of SGAinduced weight gain resulted from hyperphagia.
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1.5.2 Olanzapine Reduced Brown Adipose Tissue Thermogenesis and Locomotor
Activity in Female Rats
Recent studies have identified metabolically active BAT in adult humans, suggesting
potential clinical significance for the involvement of BAT thermogenesis in SGAinduced weight gain. However, to date there has been little research elucidating the
central neuronal pathways affecting BAT thermogenesis or the morphological changes
of the BAT. The present study aimed to investigate the role of BAT thermogenesis and
locomotor activity in olanzapine-induced weight gain during the prolonged time courses
of olanzapine treatment in an established female rat model. Although short- to mid-term
olanzapine treatment had no effect on BAT temperature, we observed long-term
olanzapine treatment (from day 18-34) induced a significant reduction in BAT
temperature, with an acute effect being observed between 45-150 minutes posttreatment in the long-term cohort. Additionally, in the long-term olanzapine group, the
reduced BAT temperature was accompanied by decreased UCP1 and PGC-1α
expressions in the BAT. Moreover, TH mRNA expressions in both hypothalamus and
brainstem were also down-regulated after mid- to long-term olanzapine treatment.
Further, olanzapine led to reduced percentage of brown adipocytes in BAT during midto long-term treatments. Finally, locomotor activity was reduced throughout the three
treatment cohorts. In summary, our results suggest that the reduction of BAT
thermogenesis plays an important role during the long-term of olanzapine-induced
weight gain, which was accompanied by an earlier onset of BAT adipocyte
morphological changes and biochemical changes in the hypothalamus and the
brainstem, while locomotor activity contributes to the entire olanzapine treatment
courses.
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1.5.3 Effects of Olanzapine on Elevation of Macrophage Infiltration and Proinflammation Cytokine Expression in Female Rats
As obesity and type 2 diabetes are associated with low-grade inflammation, and
olanzapine-induced weight gain has three typical stages, the current study investigated
the inflammatory effects of olanzapine through three different stages of treatments.
Female Sprague-Dawley rats were treated orally with olanzapine (1mg/kg; t.i.d.) or
vehicle for 1 week, 2 weeks, and 5 weeks. Olanzapine significantly increased
percentage body weight gain and visceral WAT weight in all three time courses.
Olanzapine enhanced average adipocyte size and macrophage infiltration in WAT, with
levels of macrophage infiltration increased over time. The adipocyte size and
macrophage infiltration rate were highly correlated. Olanzapine also led to increased
macrophage infiltration in BAT, but not liver. Further, pro-inflammation cytokines
TNFα, IL-1β and IL-6 were upregulated by olanzapine in hypothalamus, WAT and
BAT, but not liver. Finally, plasma triglycerides, but not total, HDL or LDL cholesterol
levels, were elevated by olanzapine. These findings indicate that olanzapine-induced
inflammation and adiposity are closely related, and peripheral low-grade inflammation
is developed over the time course of olanzapine treatment.
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1.5.4 Summary
In conclusion, the time-related effects of olanzapine on numerous aspects affecting body
weight gain, including food intake, energy expenditure and inflammation, can be
reflected in a female rat model of olanzapine-induced weight gain. Olanzapine treatment
can upregulated ghrelin production and central ghrelin signalling during the early stage
of treatment, which contribute to the rapid food intake increase and body weight gain at
this stage. Central injection of a ghrelin receptor antagonist is dose-dependently
effective in reversing the hyperphagic effect of olanzapine, which may be used as a
target for attenuating olanzapine-induced body weight gain, especially at the early stage
of treatment. At the late stage of olanzapine treatment, reduced BAT thermogenesis was
evidenced, which was accompanied by downregulation of sympathetic signals from the
hypothalamus and brainstem to the BAT and reduced brown adipocyte percentage in
BAT at the mid- to long-term of olanzapine treatment, indicating the reduced BAT
thermogenesis may contribute to olanzapine-induced weight gain at the late stages.
Locomotor activity was reduced by olanzapine throughout the three stages of treatment.
Finally, macrophage infiltration in visceral WAT and BAT was increased by olanzapine
throughout the three stages, with the levels of infiltration increased over time, which
may be the result of the increased adiposity induced by olanzapine. Further, mRNA
expressions of pro-inflammation cytokines TNFα, IL-1β and IL-6 were also increased in
visceral WAT, BAT and hypothalamus throughout the time courses of olanzapine
treatment, indicating that peripheral and central low-grade inflammation may also play a
role in olanzapine-induced weight gain, especially at the stage of heavy weight
maintenance.
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CHAPTER TWO
Hypothalamic Ghrelin Signalling Mediates Olanzapine-Induced
Hyperphagia and Weight Gain in Female Rats
Reprinted from International Journal of Neuropsychopharmacology, 17(5), Zhang Q,
He M, Deng C, Wang H, Lian J and Huang XF, Hypothalamic ghrelin signalling
mediates olanzapine-induced hyperphagia and weight gain in female rats, 807-818,
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CHAPTER THREE
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CHAPTER FOUR
Effects of Olanzapine on Elevation of Macrophage Infiltration and Proinflammation Cytokine Expression in Female Rats
Accepted for publication by Journal of Psychopharmacology, Zhang Q, He M, Deng C,
Wang H and Huang XF, Effects of olanzapine on elevation of macrophage infiltration
and pro-inflammation cytokine expression in female rats. (See online version at:
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Abstract
The metabolic side-effects of olanzapine have undermined drug compliance and
increased concern for this otherwise-effective treatment for schizophrenia. As obesity
and type 2 diabetes are associated with low-grade inflammation, and olanzapineinduced weight gain has three typical stages, the current study investigated the
inflammatory effects of olanzapine in three treatment stages. Female Sprague-Dawley
rats were treated orally with olanzapine (1 mg/kg; t.i.d.) or vehicle for 1 week, 2 weeks,
and 5 weeks. Olanzapine significantly increased body weight and white visceral fat
deposition in all three treatment stages compared to control. Olanzapine enhanced
average adipocyte size and level of macrophage infiltration in white adipose tissue
(WAT) compared to control, with levels of macrophage infiltration increased over time.
There was a high correlation between adipocyte size and macrophage infiltration rate.
Olanzapine also caused increased macrophage infiltration in brown adipose tissue
(BAT), but not liver. Additionally, pro-inflammatory cytokines TNFα, IL-1β, and IL-6
were upregulated by olanzapine in hypothalamus, WAT, and BAT compared to control,
but not liver. Finally, plasma triglycerides were elevated by olanzapine compared to
control, but not total cholesterol, HDL or LDL. These findings indicate that olanzapineinduced inflammation and adiposity are closely related, and that peripheral low-grade
inflammation develops during olanzapine treatment.
Keywords:
Antipsychotics; olanzapine; inflammation; adiposity; macrophage infiltration
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1. Introduction
Although second generation antipsychotics such as olanzapine and clozapine have been
widely used to treat schizophrenia and other psychiatric disorders, they have been
associated with an increased risk of metabolic side-effects such as obesity, abnormal
adiposity, and type 2 diabetes (De Hert et al., 2012; Fountaine et al., 2010; WestonGreen et al., 2013). This has caused significant concern in terms of reduced drug
compliance and increased morbidity and mortality (De Hert et al., 2012; Deng, 2013;
Weston-Green et al., 2013). In addition, both clinical (Haupt, 2006; McEvoy et al.,
2005; Pai et al., 2012) and animal studies (He et al., 2014; Huang et al., 2006; Zhang et
al., 2014a) suggest that there are three typical stages of olanzapine-induced weight gain:
(1) initial stage with a rapid increase of body weight accompanied by an elevated food
intake; (2) middle stage with slow body weight gain and no elevation of food intake;
and (3) late stage with maintenance of heavy body weight without an elevated food
intake.
Accumulating evidence has suggested that obesity and type 2 diabetes are in fact
connected to the development of low-grade inflammatory responses (Ouchi et al.,
2011). In particular, cafeteria diet-induced obesity (animals self-selecting from highly
palatable, readily available foods including cookies, candy, cheese, and processed
meats, designed to simulate the human Western diet) and metabolic syndrome have
been reported to be associated with liver and adipose tissue inflammation and
macrophage infiltration (Sampey et al., 2011). In addition, hypothalamic inflammation
has also been suggested to contribute to the pathogenesis of obesity in response to highfat feeding (Kleinridders et al., 2009).
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The effects of olanzapine on central or peripheral inflammation have been scarcely
reported. One animal study reported that female rats receiving olanzapine treatment (2
mg/kg) had elevated plasma levels of IL-8 and IL-1β, while both male and female rats
receiving olanzapine treatment demonstrated increased adiposity and macrophage
infiltration into adipose tissue (Davey et al., 2012). Another study using male rats
revealed that chronic olanzapine treatment can induce extensive macrophage infiltration
and increase TNFα mRNA expression in epididymal white adipose tissue (WAT) but
not in the liver (Victoriano et al., 2010). A clinical study reported that 14 days of
olanzapine treatment (5-10 mg/d) led to increased serum levels of tumour necrosis
factor α (TNFα) and plasminogen activator inhibitor type 1 compared to the control in
healthy male volunteers (Fountaine et al., 2010). However, these studies did not explore
the potential differential effects of olanzapine on these inflammatory markers along the
time course of the treatment, nor did they analyse the relationship between adiposity
(hypertrophy/hyperplasia) and inflammation in a female rat model of olanzapineinduced weight gain.
The present study aimed to investigate the inflammatory effects of olanzapine treatment
in an established female rat model of olanzapine-induced weight gain through its three
stages, and examine the relationship between inflammatory signals and body weight
gain or adiposity. We hypothesized that olanzapine can cause time-related increases in
macrophage infiltration, and in pro-inflammatory cytokine expression in WAT, brown
adipose tissue (BAT), the liver and hypothalamus. We also hypothesized that
olanzapine can cause morphological changes in WAT, BAT, and the liver, which are
correlated to changes in inflammatory markers. We measured and compared the
potential morphological changes of WAT, BAT, and the liver, including individual fat
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pad weights, adipocyte size, and macrophage infiltration, under olanzapine or vehicle
treatments after each of the three treatment stages. In addition, we also measured the
mRNA expression of proinflammatory markers TNFα, IL-1β, and IL-6 at the
hypothalamus, WAT, BAT, and the liver were also measured. Finally, we analysed
plasma lipid profiles, including plasma triglycerides, total cholesterol, high density
lipoprotein (HDL), and low density lipoprotein (LDL). To the best of our knowledge,
this is the first study reporting on a time-related effect of olanzapine on inflammation,
and the effect of olanzapine on the mRNA expression of inflammatory markers in the
hypothalamus, in an established female rat model of olanzapine-induced weight gain.
2. Materials and methods
2.1 Animals, diets, and drug administration
Female Sprague-Dawley rats (Animal Resource Centre, Perth, WA, Australia), initially
weighing 201-225 g, were individually housed at 22⁰C, 12-h light-dark cycle (lights on
at 07:00 h). All animals had ad libitum access to water and a standard laboratory chow
diet (3.9 kcal/g; 10% fat, 74% carbohydrate, and 16% protein). (Since the main goal of
the present study was to investigate the effect of the drug (olanzapine), but not diet, we
used a standard lab chow diet for all of our animals.) After one week of acclimatization,
animals were trained to self-administer the placebo sweet cookie-dough to ensure the
timely delivery of drugs or vehicle on the experimental days. Rats were randomised into
either olanzapine (O) or control (C) treatment groups, with three treatment duration
cohorts: short-term (8 days), mid-term (16 days), and long-term (36 days) (6 groups;
n=6/group). All of the experimental procedures were approved by the Animal Ethics
Committee, University of Wollongong, Australia, and complied with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes (Australian
Government National Health and Medical Research Council, 2004).
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A cookie-dough (3.5 kcal/g; 62% carbohydrate, 22% protein, 6% fibre, 10% vitamins
and minerals) method was employed as previously reported (Deng et al., 2012; WestonGreen et al., 2011; Zhang et al., 2014a). The cookie-dough method is a non-invasive
and effective way to administrate olanzapine, with reported sensitivity to olanzapineinduced side-effects and superior response compared to oral gavage or injection
methods (Minet-Ringuet et al., 2006; Shobo et al., 2011). Briefly, a mixture of
cornstarch (30.9%), sucrose (30.9%), gelatine (6.3%), casein (15.5%), fibre (6.4%),
minerals (8.4%), and vitamins (1.6%) was produced. Three times per day, a small
cookie-dough pellet (approximately 0.3 g) mixed with either olanzapine (1 mg/kg body
weight) (Eli Lilly, Indianapolis, IN, USA) or placebo was served to the animals. The
cookie dough contained a negligible amount of calories compared to the daily food
intake for the rats (accounting for approximately 3-4% of total daily calorie intake).
Animals were observed during the administration period to ensure their complete
consumption of the pellets. The dosage of olanzapine (1 mg/kg body weight, three times
per day) was based on our prior studies (Deng et al., 2012; Weston-Green et al., 2011).
This dosage is clinically relevant based on D2 receptor occupancy (Kapur et al., 2003),
which is equivalent to a human dosage of approximately 10 mg/day (for a 60 kg
person), according to dosage translation between species based on body surface area,
following an FDA guideline for clinical trials (Center for Drug Evaluation and Research
FDA, 2005; Reagan-Shaw et al., 2008). Body weight and food intake measurements
were obtained every second day as we reported earlier (Zhang et al., 2014a).
In this study, rats were closely housed in a room occupied by only female rats. Under
this rearing condition, our pre-experiments have shown that the ovarian cycles of all of
the female rats are synchronized. Therefore, although we did not directly measure the
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sex hormone levels, we should expect no significant difference between the groups due
to synchronized their ovarian cycles.
2.2 Euthanasia and tissue collection
Two hours after the last 07:00 h treatment, the rats were euthanized by fast CO2
infusion (Deng et al., 2012; Han et al., 2008; Weston-Green et al., 2011). Brains were
dissected on an ice plate immediately after euthanasia, snap-frozen in liquid nitrogen,
and stored at -80oC. Liver, periovary WAT, perirenal WAT, omental WAT, inguinal
WAT, and interscapular BAT were dissected and weighed. Liver BAT and periovary
WAT (as a representative for visceral WAT) were cut into two halves: one half (for
mRNA analysis) was snap-frozen and stored at -80oC, and the other half (for
immunohistochemistry and histology analysis) was fixed overnight by immersion at 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The fixed samples were then
dehydrated, cleared, and embedded in paraffin.
2.3 Quantitative real-time PCR (qRT-PCR)
The qRT-PCR protocol was adopted from a previous report from our group (Yu et al.,
2013). Briefly, the total RNA from the hypothalamus, BAT, WAT, and the liver was
extracted using the Aurum total RNA mini kit (Bio-Rad Laboratories, Hercules, CA,
USA) and reverse-transcribed using the high-capacity cDNA reverse transcription kit
(AB Applied Biosystems, CA, USA). qRT-PCR was performed for TNFα, IL-1β, and
IL-6 in a 20 μl final reaction volume using SYBR green I master in a Lightcycler 480
(F. Hoffmann-La Roche Ltd, Switzerland). Primers used are listed in Supplementary
Table 1. Amplification was carried out with 45 cycles of 95°C for 10 seconds, 60°C for
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30 seconds, and 72°C for 30 seconds. The results were normalized to GAPDH, which
served as the internal control. The experiments were performed in triplicate.
2.4 Histology and F4/80 Immunohistochemistry (IHC)
The paraffin-embedded tissues (in particular, liver, BAT, and WAT; n=6/group) were
section-sliced (4 μm/section) at 40 μm intervals, mounted on charged glass slides,
deparaffinized in xylene, stained for F4/80 as described by Weisberg et al. (2014), and
counter-stained briefly in hematoxylin (F4/80 is a well-characterized and extensively
referenced membrane protein for rodent macrophage analysis). Ten fields per section
(per rat) from each of the target tissues were randomly captured with a Syntec STK1160
CCD camera (Syntec Semiconductor Co. Ltd., Taipei, Taiwan) at 10x objective as
described in Zhang et al. (2014). The total number of nuclei and the number of nuclei of
F4/80-positive cells were counted for each field using the Image J 1.44 p software
(Wayne Rasband, National Institutes of Health, USA). The percentage of F4/80-positive
cells for each sample was calculated as the total number of F4/80-positive nuclei over
the total number of nuclei in the 10 randomly selected fields. For WAT, the average
adipocyte cross-sectional area was also analysed using the ImageJ 1.44 p software.
2.5 Plasma lipid profile
Blood samples were obtained by puncturing the right ventricle of the heart, collected in
EDTA coated tubes, and centrifuged at 3,000 rpm at 22°C for 25 minutes. HDL was
isolated from the plasma with dextran sulphate and magnesium chloride, based on a
modified method from Sjoblom and Eklund (Sjoblom et al., 1989). Total plasma
cholesterol (TC), HDL and triglycerides (TG) were measured using the Konelab®
20XT automatic analyser. The TC, HDL, and TG were analysed with InfinityTM
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reagent (Thermo Fisher Scientific, Auburn, NSW, Australia). LDL was calculated using
the Friedewald formula: LDL = (TC – HDL) – (TG/2.19) (Friedewald et al., 1972).
2.6 Statistics
The statistical software SPSS (version 19, SPSS, Chicago, IL, USA) was used to
perform the analysis. Two-way ANOVA was used to determine the olanzapine and
time-related effects for tissue weight and body weight gain, TNFα, IL-1β, and IL-6
mRNA expression, percentage of F4/80-positive cells, average adipocyte size, and
plasma lipid profile. The post-hoc Tukey-HSD test was used for multiple comparisons
between the three time points of interest (short-, mid- and long-term cohorts). Levene’s
tests of equality of error variance were performed to check for heteroscedasticity. Oneway ANOVA was conducted to compare olanzapine and the control at the three time
points of interest (short-, mid- and long-term cohorts). Correlations were identified by
Pearson’s correlation. Data were expressed as mean ± SEM, and P < 0.05 was
considered statistically significant.
3. Results
3.1 Olanzapine increases visceral WAT weight and percentage body weight gain
Olanzapine treatment led to a significant increase of percentage body weight gain in the
short-, mid- and long-term cohorts compared to the control (Table 1). Two-way
ANOVA revealed that there was a significant main effect of olanzapine (F(1,30) =
25.936; P < 0.001), as well as a time-related effect (F(2,30) = 3.449; P < 0.05). There was
also a significant interaction between olanzapine and time (F(2,30) = 8.895; P < 0.01).
Total body adipose tissue weight as well as the total WAT weight were significantly
elevated by olanzapine (F(1,30) = 11.593 and F(1,30) = 11.711 for total fat and total WAT,
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respectively; both P < 0.01). There was no significant difference in BAT weight (Table
1). There was no significant time-related effect on total adipose tissue weight or total
WAT weight. Furthermore, the visceral WAT weight was significantly increased by
olanzapine (F(1,30) = 10.863; P < 0.01), while the subcutaneous inguinal WAT weight
was only significantly increased in the short- and mid-term olanzapine treatment cohorts
(Table 1). For visceral fat, the periovary WAT weight was constantly elevated by
olanzapine throughout the three treatment cohorts (F(1,30) = 10.368; P < 0.01), perirenal
WAT weight was increased by olanzapine in the short- and mid-term cohorts, and
omental WAT weight was not significantly changed in any of the treatment cohorts
(Table 1).
Table 1. Percentage difference from control in adipose tissue weight and body weight
gain
ST

MT

LT

Perirenal WAT

39 ± 8*

36 ± 11*

25 ± 6

Periovary WAT

36 ± 9*

53 ± 12**

35 ± 6*

Omental WAT

24 ± 16

10 ± 12

5 ± 12

Total Visceral WAT

36 ± 4**

42 ± 14*

29 ± 5*

Subcutaneous WAT
(Inguinal WAT)

24 ± 3**

44 ± 14*

16 ± 6

Total WAT

33 ± 4**

42 ± 12**

26 ± 6*

BAT

-22 ± 4

19 ± 12

16 ± 7

Total Fat

30 ± 4**

42 ± 11*

26 ± 5*

Total Body Weight Gain

268 ± 37***

76 ± 16***

32 ± 8*

The percentage change in adipose tissue weight and total body weight gain (mean ±
SEM) in rats treated with olanzapine for ST, MT, and LT (n=6/group). ST: short-term, 1
week; MT: mid-term, 2 weeks; LT: long-term, 5 weeks; WAT: white adipose tissue;
BAT: brown adipose tissue. Total visceral WAT includes perirenal WAT, periovary
WAT, and omental WAT. Total WAT includes visceral WAT and subcutaneous WAT.
Total fat includes WAT and BAT. *P < 0.05; **P < 0.01; ***P < 0.001 vs. control. The
levels were given relative to vehicle-treated rats that were defined as 100%.
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3.2 Olanzapine increases adipocyte size and macrophage infiltration in WAT
The average adipocyte cell area in WAT was significantly increased by olanzapine
treatment in all of the cohorts (F(1,30) = 61.756; P < 0.01; Figure 1A, 1B), but with no
time-related effect. In addition, as detected by IHC of F4/80, macrophage infiltration
was evident in the olanzapine treatment groups during the three treatment cohorts (F(1,30)
= 56.400; P < 0.001; Figure 1A, 1C). There was a significant time-related effect (F(2,30)
= 4.528; P < 0.05), and the interaction effect approached significance (F(2,30) = 3.142; P
= 0.058). The percentage of F4/80-positive cells in WAT was significantly elevated by
olanzapine (with a difference of 8%, P < 0.05; 13%, P < 0.001; and 20%, P < 0.01
between olanzapine and control for short-, mid- and long-term, respectively) (Figure
1C).
Interestingly, Pearson’s correlation showed that the percentage of F4/80+ cells was
positively correlated with the average adipocyte size in WAT (r = 0.942, P < 0.001;
Figure 1D). This significant positive correlation persisted when the data were analysed
separately by treatment cohorts (r = 0.915, P < 0.001 and r = 0.860, P < 0.001 for the
control group and olanzapine group, respectively), suggesting a close relationship
between WAT inflammation and adiposity. The percentage of F4/80+ cells in WAT was
not significantly correlated with cumulative body weight gain (P = 0.079) (data not
shown).
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Figure 1. Macrophages infiltration and adipocyte enlargement in periovary WAT of
female Sprague-Dawley rats treated with olanzapine. (A) Immunohistochemical detection of
F4/80-positive cells counter-stained with hematoxylin. (B) Average adipocyte size of periovary
WAT. (C) Percentage of F4/80-positive cells in periovary WAT. (D) The correlations between
average adipocyte size and percentage F4/80-positive cells in periovary WAT. ST: short-term;
MT: mid-term; LT: long-term; C: control; O: olanzapine; WAT: white adipose tissue. *P<0.05,
**P<0.01, ***P<0.001 vs control. n=6/group.

3.3 Olanzapine causes macrophage infiltration in BAT but not liver tissue
The percentage of F4/80-positive cells in BAT was significantly increased by
olanzapine treatment (F(1,30) = 35.303; P < 0.001), with a difference of 6% (P < 0.05),
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8% (P < 0.05) and 15% (P < 0.01) in the short-, mid- and long-term, respectively
(Figure 2A, 2B). There was a significant time-related effect (F(2,30) = 3.685; P < 0.05),
but no interaction effect. However, in the liver, there was no significant difference in
terms of the percentage of F4/80-positive cells (Figure 3A, 3B).

Figure 2. Macrophages infiltration in BAT of female Sprague-Dawley rats treated
with olanzapine. (A) Immunohistochemical detection of F4/80-positive cells counterstained with hematoxylin. (B) Percentage of F4/80-positive cells in BAT. ST: shortterm; MT: mid-term; LT: long-term; C: control; O: olanzapine; BAT: brown adipose
tissue. *P<0.05, **P<0.01 vs control. n=6/group.

_____________________________________________________________________________
Qingsheng Zhang

83

Figure 3. Immunohistrochemistry staining of F4/80 in livers of female SpragueDawley rats treated with olanzapine. (A) Immunohistochemical detection of F4/80positive cells counter-stained with hematoxylin. (B) Percentage of F4/80-positive cells
in liver. ST: short-term; MT: mid-term; LT: long-term; C: control; O: olanzapine.
n=6/group.

3.4 Olanzapine increases the mRNA expression of TNFα, IL-1β, and IL-6 in the
hypothalamus, WAT, and BAT, but not in the liver
In the hypothalamus, the mRNA expression of TNFα was significantly elevated by
olanzapine treatment (F(1,30) = 33.319; P < 0.001), with a difference of 47% (P < 0.05),
69% (P < 0.05) and 91% (P < 0.01) in the short-, mid- and long-term, respectively;
Figure 3a). In addition, hypothalamic IL-1β mRNA expression was significantly
elevated by olanzapine by 95% (P<0.05), 101% (P<0.01) and 133% (P<0.01) in the
short, mid- and long-term, respectively (F(1,30) = 46.853; P < 0.001; Figure 3a).
Hypothalamic IL-6 mRNA expression was also elevated by olanzapine by 44% (P <
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0.05), 62% (P < 0.01) and 89% (P < 0.001) in the short, mid- and long-term,
respectively (F(1,30) = 48.665; P < 0.001; Figure 4A).
Similarly, in WAT, the mRNA expression of TNFα, IL-1β, and IL-6 were significantly
elevated by olanzapine treatment throughout the three treatment stages (F(1,30) = 25.225,
F(1,30) = 24.419 and F(1,30) = 36.815, respectively; all P < 0.001; Figure 4B). Similar
results were found in BAT, where TNFα, IL-1β, and IL-6 mRNA expression were
significantly upregulated by olanzapine treatment (F(1,30) = 30.236, F(1,30) = 22.071 and
F(1,30) = 25.391, respectively; all P < 0.001; Figure 4C). However, there was no
significant difference in the liver mRNA expression of TNFα, IL-1β, or IL-6 between
olanzapine and the control (Figure 4D).

Figure 4. mRNA expressions of TNFα, IL-1β and IL-6 in (A) hypothalamus, (B)
periovary WAT, (C) BAT and (D) liver. ST: short-term; MT: mid-term; LT: long-term; C:
control; O: olanzapine; WAT: white adipose tissue; BAT: brown adipose tissue; TNFα:
tumour necrosis factor α; IL-1 β: interlukin-1 β; IL-6: interlukin-6. *P<0.05, **P<0.01,
***P<0.001 vs control. n=6/group.
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Pearson’s correlation revealed that the mRNA levels of TNFα (r = 0.521, P < 0.01), IL1β (r = 0.487, P < 0.01), and IL-6 (r = 0.415, P < 0.05) were positively correlated with
the percentage of F4/80+ cells in WAT (data not shown).
3.5 Olanzapine increases plasma triglycerides, but not total cholesterol, HDL, or LDL
levels
Plasma lipid analysis reveals that olanzapine treatment caused an elevation of plasma
triglyceride levels throughout the three treatment stages (Table 2). Two-way ANOVA
revealed that there was a significant olanzapine treatment effect (F(1,30) = 30.364; P <
0.001), although there were no significant time-related or interaction effects. However,
olanzapine did not change the plasma levels of total cholesterol, HDL, or LDL (Table
2). The plasma triglyceride level was positively correlated with the percentage of
F4/80+ cells (r = 0.379, P < 0.05), average adipocyte size in WAT (r = 0.475, P < 0.01),
and cumulative body weight gain (r = 0.611, P < 0.001) (data not shown).
Table 2. Percentage difference from control in plasma lipid profile in female rats
ST

MT

LT

TC

3±5

19 ± 10

1±3

TG

91 ± 15***

55 ± 15*

27 ± 7*

HDL

8 ± 11

24 ± 11

1 ± 10

LDL

-22 ± 13

2 ± 22

-17 ± 15

The plasma levels (mean ± SEM) of total cholesterol, triglycerides, HDL cholesterol,
and LDL cholesterol were measured in rats treated with olanzapine for ST, MT, and LT
(n=6/group). ST: short-term, 1 week; MT: mid-term, 2 weeks; LT: long-term, 5 weeks;
TC: total cholesterol; TG: triglycerides; HDL: high-density lipoprotein; LDL: lowdensity lipoprotein. *P < 0.05; ***P < 0.001 vs. control. The levels were given relative
to vehicle-treated rats that were defined as 100%.
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4. Discussion
In the present study, we showed that chronic and sub-chronic olanzapine treatment had
a significant effect on body weight gain, adiposity, and inflammatory parameters in
WAT and BAT but not in the liver. It is well-known that second generation
antipsychotics, including olanzapine, can cause numerous metabolic side-effects
including body weight gain or obesity in both humans and animal models (Deng, 2013;
Weston-Green et al., 2013; Zhang et al., 2013). Obesity has also been reported to be
associated with “low-grade” chronic inflammation (Cancello et al., 2006). Previous
studies have reported on the effect of olanzapine on macrophage infiltration and the
elevation of pro-inflammatory markers in rodents (Davey et al., 2012; Victoriano et al.,
2010). However, the present study showed for the first time the time-related effects of
olanzapine treatment on macrophage infiltration in WAT and BAT in an established
female rat model of olanzapine-induced obesity. We also showed that the mRNA
expression of pro-inflammatory markers TNFα, IL-1β, and IL-6 were upregulated by
olanzapine treatment compared to the control in the hypothalamus, WAT, and BAT, but
not in the liver. Previous studies have shown that olanzapine treatment is associated
with increased CD68 cells in WAT in male rats (Victoriano et al., 2010), and increased
plasma IL-8 and IL-1β levels, and elevated WAT CD68 and IL-6 mRNA expression in
female rats (Davey et al., 2012). These findings are consistent with the olanzapineinduced elevation of peripheral inflammation and macrophage infiltration found in the
present study.
The time-related effects of olanzapine on body weight gain and inflammation observed
in the present study are interesting. Over the duration of the treatments, olanzapine led
to a gradual reduction in the percentage cumulative weight gain compared to the
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control, while the levels of peripheral inflammation (as indicated by macrophage
infiltration in WAT and BAT) were gradually elevated. These findings indicate that the
peripheral inflammatory response may be the result, rather than the cause, of the
accumulating adiposity and body weight gain induced by olanzapine. To the best of our
knowledge, this is the first study reporting on the time-related effects of olanzapine on
inflammation. In the present study, adipocyte size (Fig. 1B) and adipose tissue weight
(Table 1) increased throughout the duration of the olanzapine treatments with no timerelated effects observed, while macrophage infiltration increased from the first week of
treatment and continued to rise until the final observed time point (week 5). Future
research into the molecular basis of these time-related effects is warranted.
The present study also showed for the first time that hypothalamic TNFα, IL-1β, and IL6 mRNA expression were upregulated by olanzapine treatment, suggesting that
olanzapine affects central inflammation. However, it is unclear in the present study
whether the elevated mRNA expression of hypothalamic pro-inflammatory cytokines is
the cause or result of body weight gain or adiposity induced by olanzapine. It has been
suggested that low-grade hypothalamic inflammation could be a possible pathogenic
condition for body weight gain, through the impairment of the central leptin and insulin
signalling pathways (Thaler et al., 2010). Nevertheless, the cause-effect relationship is
still being debated (Cancello et al., 2006; Velloso et al., 2008; Wisse et al., 2009).
Hypothalamic inflammation has also been implicated in undermining thermogenesis
(Arruda et al., 2011). Intriguingly, in the same batch of animals, we have previously
reported that olanzapine treatment can induce a reduction in BAT thermogenesis in the
mid- to long-term (Zhang et al., 2014b). Future studies are required to elucidate the
cause-effect relationship between weight gain and inflammation in the context of
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olanzapine treatment. In addition, given the positive results on macrophage infiltration
in WAT, BAT, and the hypothalamus under olanzapine treatment, future studies are
warranted that investigate the effect of olanzapine on different types of macrophages
(eg. M1, M2) and their relationship to body weight gain.
Interestingly, in the liver, there was no significant difference in terms of either
macrophage inflammation or the mRNA expression of TNFα, IL-1β ,or IL-6 between
the olanzapine and the control cohorts. Although one study has reported that
hepatosteatosis and inflammation were found in the liver of high-fat diet-fed (compared
to low-fat diet-fed) rats (Sampey et al., 2011), another study found no significant
difference in the F4/80-positive Kupffer cells within the liver between lean C57BL/6J
mice and Lepob/ob mice (Weisberg et al., 2003). This inconsistency may be due to the
different causes of obesity in the animal models used in these studies. The results of the
present study suggest that obesity which is induced by olanzapine treatment is not
associated with liver inflammation, without the choices between high-fat and low-fat
diets. Future studies are warranted to investigate the mechanism for this difference.
Plasma triglyceride levels were elevated, while total cholesterol, HDL, and LDL levels
were unaffected throughout the three olanzapine treatment time courses. Consistently, a
previous study reported that a mid-term study (2 weeks) of olanzapine treatment led to
elevated serum triglyceride levels but not elevated total cholesterol, HDL, or LDL levels
in female rats (Skrede et al., 2012). An acute study showed that olanzapine treatment
resulted in increased serum triglyceride levels but reduced cholesterol and LDL levels in
female rats, while HDL levels were not affected (Jassim et al., 2012). A long-term (6week) study suggested that olanzapine treatment increased plasma cholesterol and HDL
levels, but did not change triglyceride levels in male rats (Minet-Ringuet et al., 2006).
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Compared to the present study, these animal studies showed consistent results for the
effect of olanzapine on blood triglyceride levels, except that an elevation effect is also
evident in the long-term (5 weeks) in the present study; while the effects on cholesterol,
HDL, and LDL levels may vary, which could due to different gender of animals,
different drug administration routes and/or dosages used in different studies.
Interestingly, clinical studies have shown that chronic antipsychotic treatment
(including

olanzapine)

is

associated

with

elevated

triglyceride

levels

and

hypercholesterolemia (increased total cholesterol and LDL levels, and decreased HDL
cholesterol levels) (Albaugh et al., 2011). While elevated triglyceride levels were
evident in the present study, hypercholesterolemia was absent.
While there were significant time-related effects in olanzapine-induced body weight
gain and plasma triglyceride levels, the effect of olanzapine on adipose tissue weight,
adipocyte size, macrophage infiltration, and the mRNA expression of TNFα, IL-1β, and
IL-6 were time-independent (although there was a differential time-related effect of
olanzapine on macrophage infiltration in WAT). These differences in time-related
effects, along with the fact that WAT macrophage infiltration is significantly correlated
with adipocyte size but not cumulative body weight gain, suggest that the effects of
olanzapine on weight gain and plasma lipid profiles may be through a different pathway
compared to its effects on adiposity and inflammation. In fact, previous studies have
evidenced the effect of olanzapine on elevating adiposity without causing weight gain in
male rats (Cooper et al., 2007; Victoriano et al., 2010).
In WAT, olanzapine causes a significant upregulation of TNFα, IL-1β, and IL-6 mRNA
expression, along with macrophage infiltration and increased average adipocyte size.
The macrophage infiltration rate was highly correlated with the average adipocyte size,
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suggesting a link between inflammation and adiposity in the context of olanzapine
treatment. In fact, a positive correlation between the percentage of F4/80+ cells and
adipocyte size has been indicated in a previous report investigating macrophage
accumulation and adiposity in rodents due to either diet (DIO mice) or obesity-related
mutations (Ay/+ and Lepob/ob mice) (Weisberg et al., 2003). This strong correlation
between adipocyte size and macrophage infiltration in visceral adipose tissue indicates
that the adipose tissue macrophage paracrine pathway may play a role in the regulation
of adipocyte function under olanzapine treatment, a hypothesis warrants future studies.
In addition, there is a significant correlation between macrophage infiltration and
adipocyte size in WAT, but not between macrophage infiltration and cumulative body
weight gain. This suggests that inflammation in adipose tissue may be more closely
related to adiposity than body weight gain under olanzapine treatment.
Finally, chronic inflammation, as shown in this study, results in the activation of the
pituitary-adrenal axis and the elevation of glucocorticoids. Corticosterone induces
changes in glucose, lipid, and protein metabolism and may play a role in olanzapineinduced metabolic disorders. In fact, olanzapine treatment has been reported to increase
the plasma/serum levels of corticosterone (Assié et al., 2008; Marx et al., 2006).
Therefore, future studies investigating the role of corticosterone signalling in
olanzapine-induced metabolic side-effects are warranted.
5. Conclusions
In conclusion, the findings of this study suggest that olanzapine treatment could cause
increased adipocyte size in WAT, and a time-independent elevation of the mRNA
expression of pro-inflammatory markers TNFα, IL-1β, and IL-6 in the hypothalamus,
WAT, and BAT. This may contribute to the time-dependent macrophage infiltration in
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WAT, increasing the levels of macrophage infiltration over time. Moreover, in view of
the correlation between periovary WAT adipocyte size and macrophage infiltration, and
the lack of correlation between macrophage infiltration and cumulative weight gain, a
closer link between inflammation and adiposity compared to the link between
inflammation and body weight gain was suggested under olanzapine treatment. These
findings confirm the low-grade inflammatory response under olanzapine treatment, and
extend our knowledge of inflammation and related abnormal adiposity responses
through the three stages of obesity development under olanzapine treatment. Given the
relationship between low-grade inflammation and reduced metabolic rate and insulin
resistance, future research into specific inflammatory pathways is warranted, and
therapeutic interventions through anti-inflammatory agents could be a new target for
olanzapine-induced metabolic disorders. In fact, COX-2 inhibitors have been reported to
have favourable effects over placebo in schizophrenia and major depression in animals
(Müller et al., 2008). It may be worthwhile to investigate the effects of the co-treatment
of COX-2 inhibitors with olanzapine in reducing the metabolic side-effects of this
otherwise-effective atypical antipsychotic.
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CHAPTER FIVE

5.1 OVERALL DISCUSSION AND CONCLUSIONS
The present series of studies demonstrate that olanzapine-induced weight gain is
associated with the dysregulations of the hypothalamic ghrelin signalling system, the
BAT thermogenesis system, and the central and peripheral inflammation systems,
which affects food intake, energy expenditure and adiposity, respectively. Moreover,
these studies show that most of these changes are time-dependent or time-related,
contributing to the significant weight gain and heavy weight maintenance at different
stages of olanzapine treatments. Overall,

these studies suggest that the disruption of

the central ghrelin signalling and sympathetic signalling pathways under olanzapine
treatments shift food intake and energy expenditure towards a positive energy balance
which in favours body weight gain at different stages of the antipsychotic treatment, and
the resulting central and peripheral low-grade inflammatory response may in turn shift
the ‘set-point’ for a new energy homeostasis status, contributing to the heavy weight
maintenance over time. These findings contribute novel data towards the understanding
of the mechanisms underlining olanzapine-induced weight gain, in particular through
the three different stages of treatments (Huang et al., 2006; Pai et al., 2012), and provide
guidelines for future research on improving the pharmacological managements for
schizophrenia and other psychiatric disorders. This chapter will provide a general
discussion of the key findings of the present PhD project, as well as potential
mechanisms for olanzapine-induced weight gain along the time courses of treatments,
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based on the analysis of the systems examined (in Figure 5.1). A detailed discussion of
each study has been included in the end of Chapters 2-4. The main findings of this
thesis are summarised in Table 5.1.
Table 5.1: Summary of main findings in Chapters 2-4

Parameter
Total Weight Gain (g)
Daily Food Intake (g)
Ghrelin Signalling (% Control, INFS)
Plasma Ghrelin (pg/ml)
GHS-R1a mRNA at hypothalamus
GHS-R1a protein at hypothalamus
NPY mRNA at hypothalamus
NPY protein at hypothalamus
AgRP mRNA at hypothalamus
POMC mRNA at hypothalamus
POMC protein at hypothalamus
FOXO1 mRNA at hypothalamus
FOXO1 protein at hypothalamus
pCREBprotein at hypothalamus
BSX mRNA at hypothalamus
Energy Expenditure (% Control, INFS)
BAT Temperature (2h post-tx, ͦ C)
BAT Temperature (6h post-tx, ͦ C)
BAT UCP1 protein
BAT PGC-1α protein
TH mRNA at Hypothalamus
TH mRNA at Brainstem
% Multilocular Adipocyte at BAT
Locomotor activity (distance, cm)
Locomotor activity (velocity (cm/s)

Time Effect
Short-term Mid-term Long-term
(1 week)
(2 weeks) (5 weeks)
↑***
↑**
↑*
↑***
NSC
NSC
↑**
↑**
↑**
↑**
↑***
↑**
↓**
↓**
↑**
↑*
↑***
↑***

NSC
↑*
↑**
NSC
↑*
↑*
↓*
↓*
NSC
NSC
↑*
NSC

NSC
↑*
↑*
NSC
NSC
NSC
NSC
↓**, b
NSC
NSC
NSC
NSC

NSC
NSC
NSC
NSC
NSC
NSC
NSC
↓***
↓**

NSC
NSC
↓*
↓*
↓*
↓*
↓*
↓**
↓***

↓*
NSC
↓**
↓**
↓*
↓*
↓**
↓*
↓*
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Table 5.1 (Continued)
Parameter
Inflammation Markers (% Control)
Macrophage infiltration at WAT
Adipocyte size at WAT
Macrophage infiltration at BAT
Macrophage infiltration at Liver
TNFα mRNA at Hypothalamus
IL-1β mRNA at Hypothalamus
IL-6 mRNA at Hypothalamus
TNFα mRNA at WAT
IL-1β mRNA at WAT
IL-6 mRNA at WAT
TNFα mRNA at BAT
IL-1β mRNA at BAT
IL-6 mRNA at BAT
TNFα mRNA at Liver
IL-1β mRNA at Liver
IL-6 mRNA at Liver
Adiposity (Fat Mass, g)
Perirenal
Periovary
Omental
Total Visceral WAT
Inguinal (Subcutaneous WAT)
Total WAT
BAT
Total Fat
Plasma Lipid Profile (% Control)
TC
TG
HDL
LDL

Short-term
(1 week)

Time Effect
Mid-term Long-term
(2 weeks) (5 weeks)

↑*
↑***
↑*
NSC
↑*
↑*
↑*
↑*
↑*
↑*
↑*
↑*
↑*
NSC
NSC
NSC

↑***
↑**
↑*
NSC
↑*
↑**
↑**
↑*
↑*
↑**
↑**
↑*
↑*
NSC
NSC
NSC

↑**, a
↑**
↑**, a
NSC
↑**
↑**
↑***
↑**
↑*
↑**
↑*
↑*
↑**
NSC
NSC
NSC

↑*
↑*
NSC
↑**
↑**
↑**
NSC
↑**

↑*
↑**
NSC
↑*
↑*
↑**
NSC
↑*

NSC
↑*
NSC
↑*
NSC
↑*
NSC
↑*

NSC
↑***
NSC
NSC

NSC
↑*
NSC
NSC

NSC
↑*
NSC
NSC

Abbreviations: AgRP: Agouti-related peptide; BAT: brown adipose tissue; BSX: brainspecific homeobox; FOXO1: forkhead box O1; GHS-R1a: growth hormone
secretagogue receptor 1a (ghrelin receptor); IL-1β: interleukin 1β; IL-6: interleukin
6;INFS: in not further-specified; NPY: neuropeptide Y; NSC: no significant change;
pCREB: phosphorylated cyclic AMP response element binding protein; PGC-1α:
peroxisome proliferator-activated receptor gamma coactivator-1α; POMC: proopiomelanocortin; UCP1: uncoupling protein 1; TC: total cholesterol; TG: triglyceride;
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TH: tyrosine hydroxylase;
TNFαL tumour necrosis factor α; WAT: white adipose tissue. *P< 0.05 vs. control;
**P< 0.01 vs. control; ***P< 0.001 vs. control; asignificant time effect, with magnitude
of changes increasing over time; bsignificant time effect, with magnitude of changes
decreasing over time.
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5.1.1 Overall Discussions of Findings
In Chapter 2 we reported that olanzapine potently and time-dependently increased
circulating ghrelin levels, and altered the expressions of downstream parameters in the
hypothalamic ghrelin signalling pathways, including GHS-R1a, FOXO1, pCREB, BSX,
NPY, AgRP and POMC, which in favours of hyperphagia and weight gain. Furthermore,
most of these changes were detected at the early stage, but not the late stage, of
olanzapine treatment, which is consistent with the time-related effect of olanzapine on
increasing daily food intake. Interestingly, circulating ghrelin levels were positively
correlated with the daily food intake measured on the same day as ghrelin
measurements, suggesting a time-related association between ghrelin signalling and
hyperphagia under olanzapine treatment. These time-dependent effects of olanzapine on
circulating ghrelin levels and food intake are consistent with reports from the clinic (see
reviews by Zhang et al., 2013 and Pai et al., 2012), suggesting an elevation of both
ghrelin levels and food intake at the early stage of olanzapine treatment., but with
diminishing effects at the later stages. In addition, this hyperphagic effect of olanzapine
in the early stage of treatment can be completely reversed by icv injection of a ghrelin
receptor antagonist (D-Lys3-GHRP-6), which demonstrates for the first time that
hypothalamic ghrelin signalling is an important mediator for olanzapine-induced
hyperphagia. Consistent with the blockage of the hyperphagic effect of olanzapine, DLys3-GHRP-6 also blocked the elevation of ghrelin-signalling parameters (NPY, AgRP
and POMC). These findings suggest that ghrelin receptor antagonist or inverse agonist
can be a new pharmacological target of body weight management for schizophrenia
patients on SGAs. In fact, D-Lys3-GHRP-6 has been reported to reduce food intake and
body weight gain in rodents (Asakawa et al., 2003; Beck et al., 2004). However, further
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studies are required to investigate the chronic effect of co-administration of olanzapine
and D-Lys3-GHRP-6 (or other ghrelin receptor antagonist, such as JMV2959 (Dickson
et al., 2011; Moulin et al., 2013)), as well as other routes of administration other than
icv injection, on food intake and the ghrelin signalling system. Interestingly, a recent
report found that ablation of ghrelin cells in adult mice had no effect in food intake and
body weight (McFarlane et al., 2014). These results are in fact consistent with the
observations in our ICV injection experiment where single injection of ghrelin
antagonist D-Lys3-GHRP-6 alone had no effect on food intake. It is possible that a
negative feedback mechanism would kick in to maintain the normal/minimal food
intake once the ghrelin signalling pathway is blocked under baseline condition, which
might be a possible mechanism to prevent famine. It would be interesting to follow up
this line of evidence by ablating ghrelin cells for those animals treated with olanzapine
in the short term.
In Chapter 3 it was found that BAT temperature was reduced by olanzapine treatment in
the long term (from day 18 to 34) only, but not in the short- or mid-term. In addition
this reduction in BAT thermogenesis was accompanied by downregulation of UCP1 and
PGC-1α expressions in the BAT. These data suggest that during the early stages of
olanzapine-induced rapid weight gain, other factors such as elevated food intake (as
discussed in Chapter 2), but rather than thermogenesis, should play a major role;
however, at the late stage of heavy weight maintenance, the reduction of
thermogenesis may take over the main contributor’s role for continuing body weight
gain when the elevated food intake has dissipated. As discussed in Chapter 1 and
Chapter 3, the sympathetic pathway is critical in the control of BAT thermogenesis
(Chao et al., 2012; Shi et al., 2013). In Chapter 3, it was reported that TH mRNA
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expressions in both hypothalamus and brainstem were downregulated by olanzapine in
mid- to long-term, with reduced percentage of brown adipocytes in BAT during this
periods of treatment. These findings suggest a time-dependent inhibition of the SNS
activity under olanzapine treatment, controlling BAT thermogenesis. Moreover, as
discussed in Chapter 3, a delayed effect of olanzapine on BAT thermogenesis compared
to the relevant biochemical and morphological changes was also indicated. Given the
clinical evidence of metabolically active BAT in adult humans, the role of BAT
thermogenesis in olanzapine-induced weight gain, particularly during the late stages of
treatment, may have potential clinical relevance. In addition to BAT thermogenesis,
locomotor activity was also reduced by olanzapine throughout the time courses of the
experiments (Chapter 3), which was consistent with the both clinical studies and other
animal studies (Beasley Jr et al., 1996; Deng et al., 2012; Weston-Green et al., 2011).
This decreased locomotor activity may also contribute, at least partially, to the reduced
energy expenditure and hence the sustained body weight gain throughout the different
stages of olanzapine treatment. Collectively, the results from Chapter 3 show for the
first time that BAT thermogenesis is reduced during the late stage of olanzapine
treatment (long-term in the present time-related study), which is associated with the
biochemistry and morphological changes in BAT and the sympathetic signalling
pathways in an earlier stage (mid-term in the present time-related study). These findings
suggest that energy expenditure (in particular BAT thermogenesis) plays an important
role in the later stages of olanzapine-induced weight gain, while locomotor activity may
contribute to this side-effect during the whole periods of treatment.
Since low-grade inflammation is associated with adiposity and obesity, which may have
a reciprocally facilitative effects with body weight gain (Kleinridders et al., 2009; Ouchi
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et al., 2011; Sampey et al., 2011), Chapter 4 examined the inflammatory effect of
olanzapine in the three typical stages of treatment. It was found that olanzapine
increased average adipocyte size in WAT and macrophage infiltration rate in WAT and
BAT, with the levels of macrophage infiltration and adipocyte size in WAT highly
correlated. These findings suggest a close relationship between inflammation and
adiposity under olanzapine treatment, which is consistent with previous reports on the
association between adipocyte size and macrophage infiltration in high-fat diet-induced
obese mice (DIO mice) and obesity-related mutations (Ay/+ and Lepob/ob mice)
(Weisberg et al., 2003). In addition, Chapter 4 reported for the first time that effect of
olanzapine on macrophage infiltration (in both WAT and BAT) was enhanced over the
time course of olanzapine treatment. Time-related changes in adipocyte size, adipose
tissue weight and adipocyte cell death have been reported in DIO mice (Strissel et al.,
2007). However, in the present study, adipocyte size and visceral adipose tissue weight
were increased by olanzapine throughout the treatment periods without any time-related
effects. This discrepancy may be due to the different animal models and causes of
obesity studied (olanzapine vs. high-fat diet). Chapter 4 also reported for the first time
that the proinflammation markers (TNFα, IL-1β and IL-6) were increased by olanzapine
treatment in hypothalamus, besides WAT and BAT, which indicates olanzapine-induced
central inflammation; although it is still unclear whether this central inflammation under
olanzapine treatment is the cause or effect of body weight gain. In the clinic, it has been
reported that a low-grade hypothalamic inflammation can be a potential pathogenic
condition for body weight gain, through the impairment of the central leptin and insulin
signalling pathways (Thaler et al., 2010). Furthermore, hypothalamic inflammation has
been reported to associate with reduced thermogenesis (Arruda et al., 2011), which is
intriguingly consistent with our findings in Chapter 3 revealing that olanzapine
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treatment can reduce BAT thermogenesis at the late stages of treatment. Finally,
Chapter 4 also reported that plasma triglyceride levels were elevated by olanzapine
throughout the three treatment stages observed, which is consistent with a large clinical
study (the CATIE study) showing an elevation of plasma triglyceride levels under
chronic olanzapine treatment (Meyer et al., 2008). Interestingly, in the present study,
plasma triglyceride levels were positively correlated with macrophage infiltration and
average adipocyte size in WAT, which suggests a link between lipid profile and
adiposity and its associated WAT inflammation. Taken together, Chapter 4 suggests a
close relationship between inflammation and adiposity under olanzapine treatment,
which may also contribute to the weight gain side-effects of olanzapine, while the levels
of inflammation responses develop through the time course of olanzapine treatment.
Adding a pair-feeding study to the inflammation study would definitely improve the
conclusion of this study. However, due to the tissue availability of the pair-feeding
experiment in this study, we are not able to conduct the suggested tests on those
animals, which would be an interesting follow-up study to do. Our preliminary data
(unpublished) based on the limited available mRNA samples shows that the pair-fed
olanzapine group has a trend of increasing pro-inflammatory markers TNFα, IL-6 and
IL1β compared to the control group – indicating that short-term olanzapine treatment
may actually cause inflammation independent of adiposity. However, further studies are
required to confirm this hypothesis.
Finally, gender effects should also be considered. In the present series of studies,
ovarian cycles of the experimental animals were synchronized by closely housing the
rats in a room occupied by female rats only, which minimizes the potential effects of
sex hormones on the parameters measured in the present series of studies. However,
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given the fact that the current series of studies were conducted in female rats only,
cautious should be taken when translating these results into humans – the results and the
proposed mechanisms from this series of studies may apply to female patients only.
5.1.2 Proposed Mechanisms of Olanzapine-Induced Weight Gain in Different Stages
Olanzapine-induced weight gain is possibly through a multifactorial mechanism: not
only due to the multiple receptor-binding affinities of olanzapine, but also the multiple
etiological aspects of obesity and body weight gain (Deng, 2013; Nasrallah, 2008;
Zhang et al., 2013). The findings from the current series of studies provide some
valuable insights for this multifactorial mechanism through different stages of
olanzapine-induced weight gain. As discussed in Chapter 1 and Chapter 2, in the early
stage (short-term) of olanzapine treatment, elevated food intake is the main contributing
factor for olanzapine-induced weight gain, to which the ghrelin signalling pathway is an
important mediator (Figure 5.1A). Metabolic hormones, including ghrelin, exert their
effects on the central energy homeostasis regulation system by convening information
about energy status of the body. By affecting the levels of circulating ghrelin,
olanzapine treatment can affect energy balance by moving the central energy
homeostasis regulatory signals towards a positive energy balance state. Consistent with
the majority of clinical studies and other animal studies, circulating ghrelin levels were
elevated by olanzapine in the early stage of treatment. Interestingly, it was found in the
current series of studies that the hypothalamic ghrelin signalling pathway parameters
were also altered under short-term olanzapine treatment in favouring a positive energy
balance: upregulated FOXO1, BSX, pCREB, NPY and AgRP, and downregulated
POMC levels. Importantly, these downstream ghrelin signalling changes, as well as the
elevated food intake triggered by short-term olanzapine treatment, were completely
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blocked by intracerebroventricular injection of a ghrelin receptor antagonist. These
findings provide novel evidence towards the critical role of ghrelin signalling in
olanzapine-induced hyperphagia, which is a major contributing factor for olanzapineinduced weight gain in the early stage of treatment. At this stage of treatment, BAT
thermogenesis is not affected by olanzapine, although locomotor activity was reduced
(Chapter 3), which explains the findings in our pair-feeding experiment (Chapter 2)
where no weight gain was observed in rats treated with olanzapine in the short-term
when their food intake was purposefully kept at the same level, indicating a lack of
force for energy expenditure alone in driving body weight gain at the early stage of
olanzapine treatment. Finally, adiposity and inflammation markers were also altered at
this stage of treatment, although the magnitude of macrophage infiltration is less than
that in the later stages (Chapter 4). However, it is not clear in the current series of study
whether this inflammatory response observed under olanzapine treatment is the cause or
the effect of body weight gain.
At the middle stage (mid-term) of olanzapine treatment, daily food intake or circulating
ghrelin levels are not altered by olanzapine treatment, possibly due to a negative
feedback mechanism (Chapter 2). At this stage, BAT thermogenesis is still not altered
although the preceding biochemical changes (e.g. BAT UCP1 and PGC1a expressions)
have happened. Locomotor activity is still reduced by olanzapine at this stage (Chapter
3). Hypothalamic and peripheral inflammation responses at the WAT and BAT have
been reinforced at this stage of olanzapine treatment (Chapter 4). Taken together, at the
middle stage of olanzapine treatment, when the elevated food intake has disappeared,
locomotor activity and inflammation are probably the main drivers for the sustained but
slow-downed body weight gain (Figure 5.1B).
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At the late stage (long-term) of olanzapine treatment, when food intake is not elevated,
the reduction in energy expenditure, driven by the significant decreased BAT
thermogenesis (on top of the reduced locomotor activity) (Figure 5.1C), has become the
main force for body weight gain.

BAT thermogenesis is inhibited by olanzapine

treatment at this stage, which is highly correlated with UCP1 and PGC-1α expressions
at BAT, although the latter biochemical changes have started earlier at the mid-stage.
Interestingly, this reduction in BAT thermogenesis was also associated with
downregulation of TH mRNA at both hypothalamus and brainstem, suggesting a role of
sympathetic nervous system signalling in BAT thermogenesis. Another novel finding of
the current series of studies were the reduction of percentage multilocular adipocytes in
BAT under the mid- to long-term of olanzapine treatment, which was also positively
correlated with BAT thermogenesis. The white-to-brown transdifferentiation of
adipocytes has been evidenced during sympathetic innervation by either β adrenergic
agonist or cold stimulation (Chao et al., 2012; Nagase et al., 1996). Our findings suggest
that a reverse of this morphological change (brown-to-white transdifferentiation) may
have happened in the BAT under mid- to long-term olanzapine treatment, which may
contribute, at least partially, to the reduction of BAT thermogenesis at the late stage of
olanzapine treatment. In addition, peripheral inflammation responses (indicated by both
macrophage infiltration and pro-inflammation cytokines) in both WAT and BAT were
largely elevated by olanzapine treatment at this stage, which along with hypothalamic
inflammation(Chapter 4), may also contribute to the sustained body weight gain and
heavy weight maintenance at the late stage of olanzapine treatment (Figure 5.1C).
Finally, it is important to note that the interactions between the inflammation responses
and adiposity (Chapter 4) may also contribute to olanzapine-induced weight gain
particularly at the late stage.
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(Figure legend on next page)
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Figure 5.1 Proposed mechanisms of olanzapine-induced weight gain in the three stages of treatment
(A) In the short-term, olanzapine increased circulating ghrelin levels secreted from the stomach, possibly via the antagonistic effects on adrenergic α1/α2 receptors or muscarinic M1/M3 receptors (1), which when transported to the brain, upregulates ghrelin receptor GHSR1a expressions at the Arc of
the hypothalamus (2), leading to upregulations of ghrelin signalling parameters, including the transcriptional markers FOXO1, pCREB and BSX (3),
and the orexigenic neuropeptides NPY and AgRP (4). The upregulations of NPY/AgRP then inhibit the nearby POMC neurons at the Arc,
downregulating POMC expressions (5). The elevation of NPY/AgRP and decrease of POMC expressions both facilitate increase in food intake (6).
Olanzapine can also decrease locomotor activity (7), which leads to decrease in energy expenditure (8). Further, olanzapine can also enhance
inflammation responses at WAT, BAT and hypothalamus (9). Finally, the increase in food intake, and inflammation, together with the decrease in
energy expenditure all facilitate a rapid increase in body weight gain (10), in which food intake is the major contributor, and body weight gain may in
turn lead to further increase of peripheral and hypothalamic inflammation.
(B) In the mid-term, body weight gain may have a negative feedback on circulating ghrelin levels, which eliminated the elevation effect of olanzapine
on ghrelin levels and food intake (1). In addition, olanzapine can inhibit sympathetic signals at the hypothalamus and brainstem which controls the
thermogenic activities of BAT (2). However, reduction in BAT thermogenesis is not significant at this stage, although morphological and biochemistry
changes towards the reduction effect have happened in BAT (3). Similar to the short-term treatment, olanzapine decreases locomotor activity (4) which
leads to reduction in energy expenditure (5), and increases inflammation responses (6) at the mid-term. The reduction of locomotor activity and
elevations in inflammation may be the main driver for body weight gain at this stage, when hyperphagia starts to vanish (7).
(c) In the long-term, olanzapine continues to inhibit the sympathetic signals at the hypothalamus and brainstem (1), leading to a reduction in BAT
thermogenesis (2). In addition, locomotor activity is still reduced by olanzapine at this stage (3). Both reduced BAT thermogenesis and locomotor
activity contributes to the reduction in energy expenditure (4). Furthermore, the levels of elevation in inflammation responses continue to develop at this
stage (5). Both reduction in energy expenditure and elevation in inflammation contribute to body weight gain (6).
Abbreviations: α1-/α2-ARs: α1-/α2-adrenergic receptors; AgRP: agouti-related peptide; Arc: arcuate nucleus; BAT: brown adipose tissue; BSX: brainspecific homeobox; EE: energy expenditure; FI: food intake; FOXO1: forkhead box O1; GHSR1a: ghrelin receptor; M1R/M3R: M1-/M3-muscarinic
receptors; NPY: neuropeptide Y; pCREB: phosphorylated cAMP-responsive element-binding protein; POMC: pro-opiomelanocortin
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5.1.3 Recommendations for Future Research
Based on the findings of the current series of studies, recommendations for future
research are made as follows:
1. My results revealed that olanzapine-induced hyperphagia and dysregulation of
parameters in downstream ghrelin signalling pathways are blocked by a icv injection of
a ghrelin receptor antagonist (D-Lys3-GHRP-6), indicating a critical role of ghrelin
signalling in olanzapine-induced hyperphagia. However, future studies using GHS-R1a
or ghrelin knockout models are required to confirm this role. In addition, further studies
investigating the chronic effects of co-administration of D-Lys3-GHRP-6 (or other
ghrelin receptor antagonists such as JMV2959) and olanzapine on food intake and the
ghrelin signalling system, as well as the effects of D-Lys3-GHRP-6 (or other ghrelin
receptor antagonists) administrated via other routes other than icv injection.
2. As reviewed by our group (Zhang et al., 2013), other hypothalamic ghrelin signalling
markers, including p53, SIRT1, caramide, mTOR, AMPK, ACC, FAS, CPT1, and
UCP2, may also play a role in SGA-induced hyperphagia and weight gain (López et al.,
2008; Martins et al., 2012; Ramírez et al., 2013; Skrede et al., 2013; Velasquez et al.,
2011). Further studies are required to access the effect of olanzapine on these upstream
ghrelin signalling targets.
3. We found that olanzapine treatment has no effect on food intake during the mid- to
long-term of treatment. However, it has been reported that the effect of olanzapine in
triggering preference to a high fat/high sugar diet over chow diet in rats (Smith et al.,
2011), although controversial results have also been reported (van der Zwaal et al.,
2010). It is still possible that this non-effect was due to the restriction of available foods
_____________________________________________________________________________
Qingsheng Zhang

110

to lab chow in the present study. Future studies investigating the food-preference effects
of olanzapine, as well as its relationship to food intake and body weight gain using the
present animal model are warranted.
4. Results from the present series of studies suggest a reversed morphological change in
BAT under long-term olanzapine treatment, which may contribute to the reduced BAT
thermogenesis, possibly through the chronic inhibition of the β3-adrenoceptors
(Barbatelli et al., 2010). Future studies are required to confirm this hypothesis.
5. We found that olanzapine induced reduction of BAT thermogenesis in the long-term
only, with biochemical and morphological changes in the brain and BAT happened
from mid-term of treatment, indicating a delayed effect of olanzapine over BAT
thermogenesis. This hypothesis deserves further investigation.
6. In the present series of studies, adipocyte size and adipose tissue weight increased
throughout the time course of olanzapine treatment with no time effect observed, while
the level of macrophage infiltration increased over time with significant time effect.
Future studies into the molecular basis of these time-related effects are warranted.
7. We reported a low-grade inflammation in BAT, WAT and hypothalamus under
olanzapine treatment, alongside the body weight gain, in the present series of studies.
However, the cause-effect relationship between weight gain and inflammation has not
been investigated.
8. In the current series of studies, it was found that olanzapine-induced obese rats had
no inflammation response in the liver, which was observed in high-fat diet induced
obese rats (Sampey et al., 2011). This discrepancy may be due to the fact that there was

_____________________________________________________________________________
Qingsheng Zhang

111

no choice between high-fat and low-fat diets in the present series of studies, which is an
interesting hypothesis for future studies.
5.1.4 Conclusions
The results of the present thesis have demonstrated that alterations of food intake,
energy expenditure and inflammatory signals contribute to olanzapine’s weight gain
side-effect. A time-related effect was evidenced in most parameters measured
(summarised in Table 5.1). Olanzapine-induced body weight gain is associated with
hyperphagia at the early stage of treatment, reduced BAT thermogenesis in the late
stage of treatment, and decreased locomotor activity and elevated inflammatory
response throughout the whole treatment periods, with the level of elevation of
peripheral inflammatory response increases over time. Olanzapine induced hyperphagia
in the early stage of treatment is at least partially via the elevation of circulating ghrelin
and the alterations of expressions of parameters in the hypothalamic ghrelin signalling
pathway. However, in the mid- to late-stages of treatment, most of these changes
vanished, possibly due to a negative feedback mechanism, which is consistent with the
non-elevation in food intake under mid- to long-term of olanzapine treatment. The
present study demonstrates a mechanism of reduction in BAT thermogenesis during the
late stage of olanzapine treatment, which is associated with the down-regulation of
central sympathetic signalling molecules (e.g. TH, PGC1α and UCP1) as well as the
morphological changes in BAT (i.e. the brown-to-white transdifferentiation of the
adipocytes) since the middle stage of treatment through to the late stage. This reduction
in BAT thermogenesis may make a major contribution towards the heavy weight
maintenance in the late stage of olanzapine treatment, along with the reduced locomotor
activity throughout the whole treatment periods, both leading to the reduced energy
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expenditure. A final piece of the olanzapine-induced weight gain puzzle is the increased
adiposity (especially visceral adiposity) during the whole treatment periods. In the
present study, olanzapine treatment is associated with a time-related elevation of the
inflammation responses (i.e. increased macrophage infiltration in WAT and BAT),
which is highly correlated with the enhanced adiposity. Taken together, a number of
clinical relevant metabolic changes were evident in a female rat model of olanzapineinduced weight gain, including hyperphagia, reduced energy expenditure, and enhanced
adiposity. The present study provides innovative insights into the molecular
mechanisms of these changes through different stages of olanzapine treatment,
underlying new directions for future research to improve this metabolic side-effect
through different stages of olanzapine treatment and enhance the treatment outcomes
and quality of life for patients using this antipsychotic drug. While the present study
focuses on understanding the mechanism of antipsychotic-induced obesity, it is
noteworthy that, as mentioned in the introduction of this thesis, metabolic risks are
higher in schizophrenia patients even without the effect of antipsychotics (American
Diabetes Association et al., 2004); therefore, further studies investigating the effects of
olanzapine on a rodent model with schizophrenia phenotype would be warranted to give
a more comphrehensive picture of the pathogenesis of this metabolic disorder.
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APPENDIX I
The Role of Ghrelin Signalling in Second-Generation AntipsychoticInduced Weight Gain
Reprinted from Psychoneuroendocrinology, 38, Zhang Q, Deng C and Huang XF, The
Role of Ghrelin Signalling in Second-Generation Antipsychotic-Induced Weight Gain,
2423-2438, Copyright (2013), with permission from Elsevier.
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